Page last updated: 2024-11-04

felodipine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Felodipine is a dihydropyridine calcium channel blocker used primarily to treat hypertension. It is synthesized through a multi-step process involving the reaction of 2,6-dimethylpyridine with ethyl acetoacetate, followed by a series of reactions including nitration, reduction, and cyclization. Felodipine selectively inhibits the influx of calcium ions into vascular smooth muscle cells, leading to vasodilation and a decrease in blood pressure. It is considered effective for treating hypertension, especially in patients with angina pectoris, and is also used for the treatment of Raynaud's phenomenon. Felodipine is studied extensively to understand its effects on various cardiovascular conditions and explore its potential use in other areas like cancer treatment. Its effectiveness, safety profile, and potential for drug interactions are also subject to ongoing research.'

Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3333
CHEMBL ID1480
CHEMBL ID3196476
CHEBI ID585948
SCHEMBL ID26398
SCHEMBL ID13460298
MeSH IDM0024118

Synonyms (196)

Synonym
BIDD:GT0733
MLS001333735
MLS002153832
MLS001077361
MLS002153409
BRD-A30815329-001-03-0
smr000058204
logimax
cgh-869
h-154/82
ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate
AE-641/11429675 ,
EU-0100508
felodipine, solid
brn 4331472
plendil depottab
dl-felodipine
munobal
prevex
h 154/82
perfudal
hydac
penedil
plendil
3,5-pyridinedicarboxylic acid, 1,4-dihydro-4-(2,3-dichlorophenyl)-2,6-dimethyl-, ethyl methyl ester
3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester, (+-)-
preslow
plendil retard
felodipina [inn-spanish]
felogard
feloday
renedil
felodipinum [inn-latin]
felodur er
splendil
munobal retard
(+-)-ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
agon
flodil
plendil er
modip
agon sr
3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester
c18h19cl2no4
PRESTWICK3_000478
PRESTWICK2_000478
felodipine
PRESTWICK_797
cas-72509-76-3
BPBIO1_000678
BSPBIO_000616
LOPAC0_000508
72509-76-3
(+/-)-ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
DB01023
4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester
felodipine (jp17/usp/inn)
D00319
plendil (tn)
MLS000069629 ,
SPBIO_002555
PRESTWICK1_000478
PRESTWICK0_000478
NCGC00093906-02
NCGC00093906-01
NCGC00015455-03
HMS2089J05
F 9677 ,
AC-2124
felodipina
CHEBI:585948 ,
felodipinum
NCGC00015455-08
nsc-760343
CHEMBL1480
c08ca02
4-(2,3-dichloro-phenyl)-2,6-dimethyl-1,4-dihydro-pyridine-3,5-dicarboxylic acid 3-ethyl ester 5-methyl ester
o5-ethyl o3-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
FT-0668475
FT-0660933
HMS1569O18
5-o-ethyl 3-o-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
NCGC00024087-02
HMS3261F17
HMS2096O18
HMS3259F12
ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
F0814
EN300-70726
nsc 760343
unii-ol961r6o2c
ol961r6o2c ,
felodipine [usan:usp:inn:ban]
pharmakon1600-01505887
nsc760343
tox21_110155
dtxsid4023042 ,
dtxcid303042
3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
CCG-204599
HMS2232D24
NCGC00015455-07
NCGC00015455-06
NCGC00015455-04
NCGC00015455-05
BCP9000680
plandil
felodipine [usan:ban:inn]
smr002529504
MLS003876820
FT-0626393
LP00508
S1885
AKOS015891545
gtpl4190
felodipine [ep monograph]
lexxel component felodipine
3,5-pyridinedicarboxylic acid 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, ethyl methyl ester, (+/-)-
felodipine [usan]
felodipine [orange book]
felodipine [mart.]
felodipine [usp monograph]
felodipine [inn]
felodipine [jan]
felodipine [vandf]
felodipine [mi]
felodipine [usp impurity]
felodipine [who-dd]
felodipine component of lexxel
felodipine [usp-rs]
CA-236
HY-B0309
NC00721
SCHEMBL26398
NCGC00015455-10
tox21_110155_1
KS-1264
SCHEMBL13460298
tox21_500508
NCGC00261193-01
3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-ethyl-5-methylester
4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinecarboxylic acid ethyl methyl ester
felodipine (dl form)
(.+/-.)-felodipine
3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate #
(.+/-.) ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
HB1222
AC-24403
CHEMBL3196476
OPERA_ID_1873
ethyl methyl (4rs)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
mfcd00868316
bdbm189379
SR-01000075890-1
sr-01000075890
felodipine, united states pharmacopeia (usp) reference standard
felodipine, european pharmacopoeia (ep) reference standard
HMS3651O21
Z239864852
SR-01000075890-4
HMS3713O18
SW219299-1
Q420644
SY053174
felodipine (plendil)
2,6-dimethyl-1,4-dihydropyridine-
3,5-dicarboxylate
felodipine,(s)
3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-
BCP02192
SDCCGSBI-0050492.P002
perfuda
HMS3884I14
NCGC00015455-24
plendil;renedil
BCP22685
felodipine 100 microg/ml in acetonitrile
(rs)-3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
felodipine- bio-x
BF164445
3-ethyl5-methyl4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
PD002997
PD033051
felodipine extended-release tablets
felodipine (usan:usp:inn:ban)
felodipine (ep monograph)
felopdipine
felodipine (mart.)
felodipinum (inn-latin)
felodipineextended-release tablets
felodipine (usp impurity)
felodipine (usp monograph)
felodipine (usp-rs)
felodipina (inn-spanish)
felodipino

Research Excerpts

Overview

Felodipine (FLD) is a poorly water-soluble drug. It is a calcium channel blocker used together with metoprolol succinate for treatment of hypertension.

ExcerptReferenceRelevance
"Felodipine is a calcium channel blocker with antioxidant and anti-inflammatory properties. "( Effect of felodipine on indomethacin-induced gastric ulcers in rats.
Akbaş, EM; Akbaş, N; Gülaboğlu, M; Mammadov, R; Süleyman, B; Süleyman, H, 2023
)
2.76
"Felodipine is a calcium channel blocker used together with metoprolol succinate for treatment of hypertension."( Development and Validation of RP-HPLC and an Ecofriendly HPTLC Method for Simultaneous Determination of Felodipine and Metoprolol Succinate, and their Major Metabolites in Human Spiked Plasma.
Abdelaleem, EA; Emam, AA; Hassan, ES; Naguib, IA, 2020
)
2.22
"Felodipine is a dihydropyridine Ca"( Protective and therapeutic effect of felodipine against bleomycin-induced pulmonary fibrosis in mice.
Ishihara, T; Kanda, Y; Kawahara, M; Kurotsu, S; Mizushima, T; Niino, T; Sugizaki, T; Takafuji, A; Takayama, T; Tamura, F; Tanaka, KI, 2017
)
1.45
"Felodipine is a substrate of CYP3A4, and naringenin was reported to be a modulator of P-gp and CYP3A4."( Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro.
Naveen Babu, K; Puneeth, Y; Ravindra Babu, P; Sridhar, V; Surya Sandeep, M, 2014
)
1.41
"As felodipine is a poorly water soluble drug, its molecular dispersion in a soluble polymer (ie."( Inkjet printing as a novel medicine formulation technique.
Alexander, MR; Gellert, PR; Roberts, CJ; Scoutaris, N, 2011
)
0.88
"Felodipine (FLD) is a poorly water-soluble drug. "( Micronization and microencapsulation of felodipine by supercritical carbon dioxide.
Cheng, HC; Chiou, AH; Wang, DP, 2006
)
2.04
"Felodipine is a vasodilator antihypertensive agent which, in doses which decrease mean arterial pressure in normotensive rats, increases urinary flow rate and sodium excretion by inhibiting distal tubular and collecting duct sodium and water reabsorption; potassium reabsorption or excretion is not affected."( Renal tubular site of action of felodipine.
Dibona, GF; Sawin, LL, 1984
)
1.27
"Felodipine is a new calcium antagonist with a high degree of vascular selectivity. "( Acute haemodynamic and metabolic effects of felodipine in congestive heart failure.
Campbell, S; Jewitt, DE; Monaghan, MJ; Timmis, AD; Walker, L, 1984
)
1.97
"Felodipine is a fluorescent dihydropyridine Ca2+-antagonist. "( Allosteric interactions among drug binding sites on calmodulin.
Johnson, JD, 1983
)
1.71
"Felodipine is a new generation 1,4 dihydropyridine (1,4 DHP) Ca(2+)-entrance blocker with marked vascular selectivity."( Felodipine and vasomotion physiology.
Karatzas, D; Kokkas, B; Kotoula, M; Kouvelas, D; Kouyoumtzis, A; Papadopoulos, C; Paradelis, A, 1993
)
2.45
"Felodipine is a highly vascular selective calcium entry blocker, with a vascular selectivity ratio greater than 100, as shown experimentally."( Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine.
Cheng, CP; Elvelin, L; Little, WC; Nordlander, M, 1995
)
1.23
"Felodipine is a second-generation dihydropyridine calcium antagonist with a high degree of vascular selectivity which, in the doses used in this study, exerts its systemic arterial effect by decreasing peripheral vascular resistance without producing negative inotropic effects."( Rationale and design of the third vasodilator-heart failure trial (V-HeFT III): felodipine as adjunctive therapy to enalapril and loop diuretics with or without digoxin in chronic congestive heart failure. V-HeFT III investigators.
Boden, WE; Carson, PE; Cohn, JN; Conrad, CH; Syat, D; Ziesche, S, 1996
)
1.24
"Felodipine appears to be a highly potent, well tolerated drug and offers a substitute treatment for severe hypertensives refractory to other vasodilators."( Felodipine in the treatment of severe refractory hypertension.
Carroll, J; Grossman, E; Katz, A; Nussinovitch, N; Rachima, C; Rosenthal, T; Shamiss, A, 1996
)
2.46
"Felodipine is a calcium channel inhibitor with high vascular selectivity."( [Felodipine in the treatment of essential arterial hypertension in elderly patients].
Fasce, E; Fasce, M; Peña, L, 1996
)
2.65
"Felodipine is a second-generation dihydropyridine calcium antagonist used to treat mild to moderate arterial hypertension. "( Effect of felodipine on arterial blood flow and venous function at rest in patients with mild essential hypertension.
Arrigucci, S; Bicchi, M; Cappelli, R; Forconi, S; Righi, GA; Vedovini, G, 1998
)
2.15
"Felodipine is a calcium antagonist, one of the dihydropyridines, with potential application in transdermal therapeutic systems (TTS). "( Influence of d-limonene on the transdermal penetration of felodipine.
Diez, I; Domenech, J; Obach, R; Peraire, C,
)
1.82
"Felodipine is a calcium channel blocking agent used in the management of hypertension and angina. "( Felodipine-induced gingival hyperplasia.
Benson, PM; Liebman, MD; Sau, P; Turiansky, GW; Young, PC, 1998
)
3.19
"Felodipine is a vascular-selective, dihydropyridine calcium antagonist previously investigated as a conventional tablet formulation administered twice daily. "( Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.
Faulds, D; Todd, PA, 1992
)
3.17
"Felodipine is a dihydropyridine calcium antagonist which may be administered once daily in an extended release (ER) formulation. "( Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in older patients.
Faulds, D; Sorkin, EM,
)
3.02
"Felodipine is a new dihydropyridine calcium channel blocker with a number of properties that enhance its suitability as a first-line antihypertensive drug for the elderly. "( Efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients.
DeQuattro, V, 1992
)
2.04
"Felodipine is a dihydropyridine calcium antagonist which lowers total peripheral resistance and blood pressure in doses which have no effect on cardiac conduction and contractility. "( Renal effects of felodipine--a review.
Edgar, B; Elmfeldt, D; Nordlander, M, 1992
)
2.07
"Felodipine is a new calcium antagonist with vascular selectivity. "( Vascular selectivity of felodipine: clinical experience.
Sheridan, DJ; Thomas, P, 1990
)
2.03
"Felodipine is a new calcium antagonist that was developed aiming particularly at reduction in vascular resistance-without any decrease in heart pump function. "( Hemodynamic effects of felodipine in hypertension: a review.
Lund-Johansen, P, 1990
)
2.03
"Felodipine is a dihydropyridine that blocks the slow entry channel for calcium. "( A review of the antihypertensive effects of felodipine alone or in combination.
Morgan, TO, 1990
)
1.98
"Felodipine is a calcium antagonist that has potentially beneficial effects in angina pectoris and congestive heart failure."( The safety of felodipine.
Lorimer, AR; Pringle, SD, 1990
)
1.36
"Felodipine is a vasodilating calcium channel blocker of the dihydropyridine type. "( Attenuation of renal ischaemic injury by felodipine.
Nordlander, MI; Sohtell, ME; Svensson, LE; Thalén, PG, 1991
)
1.99
"Felodipine is a novel dihydropyridine calcium-channel antagonist with vascular selectivity."( Felodipine prevents the poststenotic myocardial ischemia induced by alpha 2-adrenergic coronary constriction.
Ehring, T; Heusch, G, 1990
)
2.44
"Felodipine (Plendil) is a once daily antihypertensive calcium antagonist. "( Felodipine as monotherapy in Asian patients with mild to moderate hypertension.
Tan, AT; Woo, BY; Yeoh, TK, 1990
)
3.16
"1. Felodipine is a new calcium-antagonist dihydropyridine derivative with a high degree of selectivity for smooth muscle of arteriolar resistance vessels, as opposed to cardiac cells. "( Felodipine ER formulation in the treatment of mild hypertension: efficacy and tolerability vs placebo.
Bossini, A; Cagli, V; Cavallotti, G; Di Veroli, C, 1990
)
2.34
"Felodipine is a potent arteriolar vasodilator. "( The positive inotropic effect of felodipine in isovolumically beating dog heart.
Björkman, JA; Drake-Holland, AJ; Hynd, J; Noble, MI; Pettersson, K, 1987
)
2
"Felodipine is a potent arteriolar dilator with therapeutic advantages, especially for patients with moderate to severe hypertension."( Felodipine in hypertension--a review.
Elmfeldt, D; Hedner, T; Westerling, S, 1987
)
2.44
"Felodipine is a potent, but relatively slow, relaxation agent in rat caudal artery, decreasing 30 mM K+ contractions by 39% at a concentration of 1 nM and 88% at 10 nM. "( Felodipine actions on vascular muscle Ca2+ channels.
Hermsmeyer, K; Rusch, NJ, 1987
)
3.16
"Felodipine is a dihydropyridine calcium antagonist that exerts a markedly selective inhibition of the smooth muscle of arterial resistance vessels. "( Felodipine sensitivity in vivo and in vitro of activation pathways in vascular smooth muscles.
Johansson, B; Ljung, B; Nordlander, M, 1987
)
3.16
"Felodipine was shown to be a well-tolerated, effective antihypertensive agent when used with a beta-blocking drug and to be suitable for people with hypertension who fail to be controlled with a beta-blocking drug."( Felodipine compared to prazosin as additional therapy to a beta-blocking drug.
Bune, A; Chalmers, J; Heath, W; Jackson, B; Johnston, C; Mashford, ML; McGrath, B; West, M; Westwood, B; Wing, L, 1987
)
2.44
"Felodipine-ER once daily is an effective antihypertensive drug for patients who require therapy in addition to a beta-blocker; the tolerability in this study was good, and a starting dose greater than 10 mg once daily is not indicated."( A dose-finding, placebo-controlled study on extended-release felodipine once daily in treatment of hypertension.
Barnes, P; Cambell, LM; Goves, JR; Lees, CT; McCullagh, A; Richardson, PD; Ross, JR; Timerick, SJ, 1989
)
1.24
"Felodipine is a highly selective dihydropyridine calcium antagonist effective in the treatment of hypertension."( A trial of the calcium antagonist felodipine in hypertensive type 2 diabetic patients.
Capewell, S; Clarke, BF; Collier, A; Collier, R; Hajducka, C; Matthews, D; Muir, AL, 1989
)
1.28
"Felodipine is a new dihydropyridine calcium antagonist which selectively relaxes vascular smooth muscle. "( [Felodipine in arterial hypertension. Double-blind comparison with atenolol].
Andrejak, M; Lesbre, JP; Morand, P; Raveau-Landon, C; Witchitz, S,
)
2.48
"Felodipine is a dihydropyridine calcium antagonist which has a positive inotropic effect in the dog in vivo. "( The effects of felodipine on left ventricular function in beta-blocked patients.
Drake-Holland, AJ; Mills, C; Noble, MI; Pugh, S, 1987
)
2.07
"Felodipine is an effective antihypertensive agent when used with metoprolol.(ABSTRACT TRUNCATED AT 250 WORDS)"( Hormonal and blood pressure responses to tilting in beta-blocked essential hypertension treated with felodipine or prazosin.
Jackson, B; Johnston, CI; McGrath, BP, 1987
)
1.21
"Felodipine is a dihydropyridine calcium antagonist, structurally related to nifedipine, which undergoes extensive first-pass hepatic metabolism and normally has an oral bioavailability of 15%. "( Reduced felodipine bioavailability in patients taking anticonvulsants.
Capewell, S; Critchley, JA; Freestone, S; Pottage, A; Prescott, LF, 1988
)
2.15
"Felodipine is a dihydropyridine calcium antagonist which selectively relaxes vascular smooth muscle. "( Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.
Ellrodt, AG; Langley, MS; Monk, JP; Saltiel, E, 1988
)
3.16
"Felodipine is a new calcium antagonist of the dihydropyridine group with a high selectivity for arteriolar smooth muscle; it is under clinical investigation for the treatment of hypertension."( Felodipine, a new calcium antagonist, modifies exercise-induced asthma.
Patel, KR; Peers, E, 1988
)
2.44
"Felodipine is a new dihydropyridine calcium antagonist drug with cardiovascular effects, whose pharmacokinetics and effects on plasma digoxin levels have been studied in patients with left ventricular failure."( Pharmacokinetics of felodipine and effect on digoxin plasma levels in patients with heart failure.
Billing, E; Lundman, T; Moberg, L; Olsson, G; Rehnqvist, N, 1987
)
1.32
"Felodipine is a dihydropyridine calcium antagonist that has a positive inotropic effect at low concentration in the dog in vivo."( Problem of measuring the positive inotropic property of a vasodilating drug: an illustration using felodipine.
Drake-Holland, AJ; Mills, C; Noble, MI; Pugh, S, 1987
)
1.21
"Felodipine is a high-clearance drug and the in vivo extraction ratios were about the same in all species: rat 0.80, dog 0.83 and man 0.84."( In vivo pharmacokinetics of felodipine predicted from in vitro studies in rat, dog and man.
Bäärnhielm, C; Dahlbäck, H; Skånberg, I, 1986
)
1.29
"Felodipine is a new dihydropyridine calcium antagonist, and in hypertension it is a much more effective "third-line" drug than hydralazine. "( Felodipine compared to nifedipine as "third-line drug" in resistant hypertension.
Maclean, D; Mitchell, ET; Readman, AS, 1986
)
3.16
"Felodipine is a new calcium antagonist with a high degree of vascular selectivity. "( Studies with felodipine in congestive heart failure.
Jewitt, DE; Timmis, AD, 1985
)
2.08

Effects

Felodipine has a natriuretic/diuretic effect, which counteracts the salt and water retention that is often seen during treatment with other potent vasodilators. Only felodipines ER 5 mg has a significant reducing effect on BP load during day and night time.

Felodipine has a protective effect on the myocardium and kidney as evidenced by decreased perivascular inflammation, myocardial necrosis and fibrosis. Only felodipines ER 5 mg has a significant reducing effect on BP load during day and night time.

ExcerptReferenceRelevance
"Felodipine has a very low bioavailability due to first-pass metabolism. "( Dry Gel Containing Optimized Felodipine-Loaded Transferosomes: a Promising Transdermal Delivery System to Enhance Drug Bioavailability.
Aboul-Einien, MH; El Taweel, MM; Kassem, MA, 2018
)
2.21
"Felodipine has a protective effect on the myocardium and kidney as evidenced by decreased perivascular inflammation, myocardial necrosis and fibrosis."( Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats.
Franco, M; Janicki, JS; Matsubara, BB; Matsubara, LS, 2010
)
1.48
"Only felodipine ER 5 mg has a significant reducing effect on BP load during day and night time."( Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: effect on ambulatory blood pressure and quality of life.
van der Pol, GA; van Ree, JW, 1996
)
1.1
"Felodipine has a 100-fold selectivity for inhibiting the contribution of vascular smooth muscle compared with cardiac muscle."( Efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients.
DeQuattro, V, 1992
)
1.32
"Felodipine has a dose-related effect on diastolic BP whether given alone or with a beta-blocker."( Dose-plasma concentration--effect relationship of felodipine in essential hypertension: a review.
Reid, JL, 1990
)
1.25
"Felodipine has a natriuretic/diuretic effect, which counteracts the salt and water retention that is often seen during treatment with other potent vasodilators."( Felodipine in hypertension--a review.
Elmfeldt, D; Hedner, T; Westerling, S, 1987
)
2.44
"Felodipine has a beneficial effect in patients with moderately severe heart failure."( Efficacy of felodipine in congestive heart failure.
Dunselman, PH; Hamer, JP; Kuntze, CE; Lie, KI; Scaf, AH; van Bruggen, A; Wessling, H, 1989
)
1.38
"Felodipine has a very low bioavailability due to first-pass metabolism. "( Dry Gel Containing Optimized Felodipine-Loaded Transferosomes: a Promising Transdermal Delivery System to Enhance Drug Bioavailability.
Aboul-Einien, MH; El Taweel, MM; Kassem, MA, 2018
)
2.21
"Felodipine has a protective effect on the myocardium and kidney as evidenced by decreased perivascular inflammation, myocardial necrosis and fibrosis."( Effect of felodipine on myocardial and renal injury induced by aldosterone-high salt hypertension in uninephrectomized rats.
Franco, M; Janicki, JS; Matsubara, BB; Matsubara, LS, 2010
)
1.48
"Felodipine has not been shown to be of benefit in patients with mild to moderate heart failure."( Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group.
Littler, WA; Sheridan, DJ, 1995
)
2.03
"Only felodipine ER 5 mg has a significant reducing effect on BP load during day and night time."( Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: effect on ambulatory blood pressure and quality of life.
van der Pol, GA; van Ree, JW, 1996
)
1.1
"Felodipine ER has been well studied in patients with essential hypertension."( Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.
Faulds, D; Todd, PA, 1992
)
2.45
"Felodipine ER has generally been well tolerated by older patients in clinical trials, although further confirmation in the long term is desirable."( Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in older patients.
Faulds, D; Sorkin, EM,
)
2.3
"Felodipine has a 100-fold selectivity for inhibiting the contribution of vascular smooth muscle compared with cardiac muscle."( Efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients.
DeQuattro, V, 1992
)
1.32
"Felodipine has a dose-related effect on diastolic BP whether given alone or with a beta-blocker."( Dose-plasma concentration--effect relationship of felodipine in essential hypertension: a review.
Reid, JL, 1990
)
1.25
"Felodipine has overall a modest but significant anti-anginal benefit when combined with a beta-blocker."( The effects of felodipine in angina pectoris.
Barbour, MP; Fox, Y; Lawrie, TD; Lorimer, AR; MacFarlane, P; Pringle, S, 1990
)
1.35
"Felodipine has a natriuretic/diuretic effect, which counteracts the salt and water retention that is often seen during treatment with other potent vasodilators."( Felodipine in hypertension--a review.
Elmfeldt, D; Hedner, T; Westerling, S, 1987
)
2.44
"Felodipine has antianginal effects but these are limited and seem less than those of other related compounds."( The effects of treatment with felodipine as a single agent in coronary artery disease.
Chan-Wah-Hak, NS; Jennings, K; Metcalfe, MJ, 1989
)
1.29
"Felodipine has a beneficial effect in patients with moderately severe heart failure."( Efficacy of felodipine in congestive heart failure.
Dunselman, PH; Hamer, JP; Kuntze, CE; Lie, KI; Scaf, AH; van Bruggen, A; Wessling, H, 1989
)
1.38
"Felodipine thus has more pronounced and sustained antihypertensive effects than nifedipine, though its side effect burden may appear to be greater.(ABSTRACT TRUNCATED AT 250 WORDS)"( Felodipine compared to nifedipine as "third-line drug" in resistant hypertension.
Maclean, D; Mitchell, ET; Readman, AS, 1986
)
2.44

Actions

Felodipine might cause a retarded elimination of desmethyldiazepam, possibly by obtruding the formation of oxazepam. The felodipin-induced increase of heart rate (HR) persisted for 90 min, but the increase of stroke volume was only transient. ER felodipsine did not increase 24-hour heart rate.

ExcerptReferenceRelevance
"ER felodipine did not increase 24-hour heart rate."( Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring.
Ansuini, R; Antonicelli, R; Gesuita, R; Giovanni, DC; Mori, A; Omboni, S; Paciaroni, E; Parati, G, 2002
)
1.07
"Felodipine tended to increase U-AQP2, to decrease CH2O and urine volume and GFR, and to increase FENa, but the effect was not significantly different from placebo."( Urinary excretion of aquaporin-2 after furosemide and felodipine in healthy humans.
Bech, JN; Pedersen, EB; Starklint, J, 2005
)
1.3
"Felodipine tended to increase U-AQP2."( Urinary excretion of aquaporin-2 after furosemide and felodipine in healthy humans.
Bech, JN; Pedersen, EB; Starklint, J, 2005
)
1.3
"Felodipine was unable to inhibit the activity of myosin light chain kinase rendered Ca2+/calmodulin-independent by limited tryptic digestion."( Inhibition of turkey gizzard myosin light chain. Kinase activity by dihydropyridine calcium antagonists.
Adelstein, RS; Movsesian, MA; Swain, AL, 1984
)
0.99
"Felodipine caused an increase in plasma renin activity in each strain but the increase reached significant levels only in GH, SHR and WKY."( Effect of felodipine on blood pressure, body sodium, plasma renin activity and plasma aldosterone in hypertensive and normotensive rats.
Hamada, M; Ledingham, JM; Simpson, FO, 1995
)
1.41
"Felodipine did not cause any statistically significant changes in ET-1 levels, Tgrad, Trect, Ptc O2, flap survival or pre- or intraoperative MAP."( The effect of felodipine on endothelin-1 levels, peripheral vasoconstriction and flap survival during microvascular breast reconstruction.
Asko-Seljavaara, S; Svartling, NE; Tikkanen, IT; Tuominen, HP, 1997
)
1.38
"Felodipine does not increase reflux episodes or impair esophageal acid clearance in patients with gastroesophageal reflux disease."( Felodipine does not increase the reflux episodes in patients with gastroesophageal reflux disease.
Chang, CS; Chen, GH; Ko, CW; Poon, SK; Wu, JH,
)
3.02
"Felodipine appears to lower blood pressure effectively in the elderly patient with few, generally mild, adverse effects."( Efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients.
DeQuattro, V, 1992
)
1.32
"Felodipine might cause a retarded elimination of desmethyldiazepam, possibly by obtruding the formation of oxazepam."( The effects of felodipine on the pharmacokinetics of diazepam.
de la Rey, N; Hundt, HK; Luus, HG; Meyer, BH; Müller, FO; Röthig, HJ, 1992
)
1.36
"Felodipine does not cause orthostatic hypotension since it has no effect in clinical doses on venous smooth muscle."( Felodipine in hypertension--a review.
Elmfeldt, D; Hedner, T; Westerling, S, 1987
)
2.44
"Felodipine achieved a lower supine blood pressure (mean +/- s.d."( Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension. Cooperative Study Group.
, 1986
)
2.44
"The felodipine-induced increase of plasma renin activity (100%; p less than 0.001) was completely reversed by metoprolol."( Effects of felodipine and metoprolol on blood pressure, plasma renin, angiotensin II, aldosterone and catecholamines in hypertensive patients.
Amery, A; De Schaepdryver, A; Fagard, R; Lijnen, P; Moerman, E; Staessen, J, 1987
)
1.14
"The felodipine-induced increase of heart rate (HR) persisted for 90 min, but the increase of stroke volume was only transient."( The use of Doppler echocardiography to assess the acute haemodynamic response to felodipine and metoprolol in hypertensive patients.
Amery, A; Fagard, R; Staessen, J, 1987
)
0.98

Treatment

Felodipine treatment did not seem to cause any significant interaction with cyclosporin A (CyA) Combined treatment withcyclosporine and felodipne increased AUC and Cmax (58% and 151% respectively) and lowered mean residence time.

ExcerptReferenceRelevance
"Felodipine treatment led to a significant increase in gene expression of connexin-50 and 46 in the mouse lens."( L-type calcium channels play a critical role in maintaining lens transparency by regulating phosphorylation of aquaporin-0 and myosin light chain and expression of connexins.
de Ridder, GG; Maddala, R; Nagendran, T; Rao, PV; Schey, KL, 2013
)
1.11
"Felodipine pretreatment was able to maintain normal cardiac morphology and histoarchitecture."( Doxorubicin mediated cardiotoxicity in rats: protective role of felodipine on cardiac indices.
Balaraman, R; Gandhi, H; Mistry, N; Nandania, J; Patel, VB; Patni, N, 2013
)
1.35
"Felodipine pretreatment had no effect on the cytochrome P-450 concn."( Cytochrome P-450-dependent oxidation of felodipine--a 1,4-dihydropyridine--to the corresponding pyridine.
Bäärnhielm, C; Borg, KO; Skånberg, I, 1984
)
1.26
"Felodipine treatment did not seem to cause any significant interaction with cyclosporin A (CyA)."( Early renal graft function in recipients treated with the calcium channel blocker felodipine.
Blohmé, I; Haljamäe, U; Herlitz, H; Nordén, G; Nyberg, G, 1994
)
1.24
"For felodipine, combined treatment with cyclosporine and felodipine increased AUC and Cmax (58% and 151%, respectively) and lowered mean residence time (24%) significantly compared to felodipine alone."( Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine.
Jensen, JD; Jensen, LW; Madsen, JK; Pedersen, EB, 1996
)
1
"Felodipine pretreatment enabled an unblunted response to dobutamine."( Felodipine protects human atrial muscle from hypoxia-reoxygenation dysfunction: a force-frequency relationship study in an in vitro model of stunning.
Bernucci, P; Brancaccio, GL; Criniti, A; d'Amati, G; Dawodu, AA; Gallo, P; Gaudio, E; Iwashiro, K; Monti, F; Pannarale, L; Puddu, PE; Sinatra, R; Vetuschi, A, 1997
)
2.46
"Felodipine-treated patients decreased on the 36th month, but remained over 80%."( [The Hypertension Optimal Treatment Study: efficacy and tolerability on the 36th month].
Baguet, JP; Benkritly, A; Herpin, D; Mallion, JM; Tremel, F, 1998
)
1.02
"On felodipine treatment, dizziness was reduced but reports of flushing and oedema were increased."( Efficacy and tolerability of lisinopril compared with extended release felodipine in patients with essential hypertension. Danish Cooperative Study Group.
Jensen, HA, 1992
)
1.03
"Felodipine treatment produced a significant decrease in blood pressure in SHRSP (control SHRSP: 240 +/- 7 mmHg, n = 6; felodipine-treated SHRSP: 164 +/- 8 mmHg, n = 5, P less than 0.05; tail-cuff method)."( Effect of felodipine on blood pressure and vascular reactivity in stroke-prone spontaneously hypertensive rats.
Bruner, CA; Webb, RC, 1989
)
1.4
"The felodipine treated patients experienced more ankle swelling and flushing than those in the hydralazine group who experienced more headache and minor gastro-intestinal upset."( Felodipine vs hydralazine: a controlled trial as third line therapy in hypertension. Cooperative Study Group.
, 1986
)
2.19
"Felodipine treatment caused a reduction in the SHRSP values to WKY levels."( Effects of felodipine on blood pressure and lymphocyte membrane characteristics in spontaneously hypertensive stroke-prone rats.
Bohr, DF; Furspan, PB, 1988
)
1.39
"Treatment with felodipine decreased lactate, but increased water content."( The effect of global brain ischemia in normal and diabetic animals: the influence of calcium channel blockers.
Dunbar, JC; Levy, J; Zhu, Z, 2004
)
0.66
"Treatment with felodipine at 10(-10) and 10(-9) M had no effect on the hearts when perfused under aerobic conditions, whilst the higher dose reduced developed pressure from 57.7 +/- 2.6 to 30.0 +/- 2.6 mmHg (p < 0.01)."( Effects of felodipine on the ischemic heart: insight into the mechanism of cytoprotection.
Benigno, M; Bernocchi, P; Cargnoni, A; Ceconi, C; Ferrari, R; Gaia, G; Pasini, E; Pedersini, P, 1996
)
1.02
"Treatment with felodipine ER did not adversely affect survival in any neurohormone subclass."( Plasma norepinephrine and atrial natriuretic peptide in heart failure: influence of felodipine in the third Vasodilator Heart Failure Trial. V-HeFT III investigators.
Anand, IS; Cohn, JN; Germanson, T; Judd, D; Smith, RF; Taylor, WR; Wong, M; Ziesche, S, 2000
)
0.87
"Pretreatment with felodipine (10 or 35 mg kg-1) enhanced the 5-HT-mediated behavioural syndrome induced by injection of tranylcypromine and L-tryptophan."( The effects of Ca2+ antagonists and hydralazine on central 5-hydroxytryptamine biochemistry and function in rats and mice.
Cross, AJ; Davies, EM; DeSouza, RJ; Green, AR, 1990
)
0.6
"Treatment with felodipine ER over 2 weeks increased sympathetic outflow as indicated by elevated plasma norepinephrine levels, whereas plasma epinephrine was mainly unaffected, as were plasma renin and aldosterone levels."( Catecholamines and the renin-angiotensin-aldosterone system during treatment with felodipine ER or hydrochlorothiazide in essential hypertension.
Binner, L; Gabrielsen, F; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991
)
0.85

Toxicity

Sitting blood pressure (BP), heart rate, body weight, adverse reaction and serum biochemistry were assessed in 70 patients with mild-moderate essential hypertension. The main adverse event related to Felodipine was headache, and to Lisinopril was cough. Overall, patients in the felodipsine ER group had a higher rate of adverse reaction.

ExcerptReferenceRelevance
" Felodipine appears to lower blood pressure effectively in the elderly patient with few, generally mild, adverse effects."( Efficacy and safety of felodipine, a new dihydropyridine calcium channel blocker, in elderly hypertensive patients.
DeQuattro, V, 1992
)
1.5
"Although most clinical trials encompass aspects of safety, methods for assessing the safety of a drug by recording adverse events have been poorly studied."( Adverse event monitoring in clinical trials of felodipine and omeprazole.
Lundborg, P; Svärdsudd, K; Wallander, MA, 1992
)
0.54
" Although felodipine seems to be safe in most patients, treatment with felodipine should at present be avoided in pregnant women, since digital anomalies have been observed in rabbit fetuses."( The safety of felodipine.
Lorimer, AR; Pringle, SD, 1990
)
1.04
" Overall, losartan, whether administered alone or in combination with a low dose of hydrochlorothiazide (HCTZ), was effective and well-tolerated in these clinical trials, with an incidence of adverse experiences similar to that of placebo."( Efficacy and safety of losartan.
Goldberg, A; Sweet, C, 1995
)
0.29
"1%) were the clinical adverse experiences most often reported in patients treated with losartan."( Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.
Dunlay, MC; Goldberg, AI; Sweet, CS, 1995
)
0.5
" There were no differences between the three groups with respect to the incidence of adverse events overall or those considered treatment-related."( Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy.
Bauer, B; Poisson, P; Rangoonwala, B; Schueler, E, 1996
)
0.66
" Atenolol, a cardio-selective beta-blocker, has been shown to be a safe and effective antihypertensive agent."( Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension.
Chern, MS; Lin, FC; Wu, D, 1997
)
0.53
"Sitting blood pressure (BP), heart rate, body weight, adverse reaction and serum biochemistry were assessed in 70 patients with mild-moderate essential hypertension treated either with felodipine ER (37 patients), or atenolol (33 patients) for 10 weeks."( Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension.
Chern, MS; Lin, FC; Wu, D, 1997
)
0.72
" Overall, patients in the felodipine ER group had a higher rate of adverse reaction (70."( Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension.
Chern, MS; Lin, FC; Wu, D, 1997
)
0.83
" Drug-related adverse events were relatively infrequent, often transient, usually mild, and apparently not dose related."( Long-term efficacy, tolerability, and safety of the combination of enalapril and felodipine ER in the treatment of hypertension. Enalapril-Felodipine ER Factorial Study Group.
Cutler, NR; Davis, PJ; Gradman, AH; Michelson, EL; Robbins, JA; Weiss, RJ; Wood, BC,
)
0.36
"The primary aim of this double-blind, parallel group trial was to compare incidence of newly occurring vasodilatory adverse events in elderly patients treated with recommended once-daily doses of felodipine extended release (ER) or amlodipine."( Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group.
Aldons, PM; Burgess, ED; Girerd, X; Morgan, TO; Rehn, L; Schaefer, RM; Singh, GP; Tilvis, R, 1998
)
0.79
" Such aggressive antihypertensive treatment was safe and well tolerated, and did result in fewer cardiovascular events in the subset of patients with diabetes."( Aggressive blood pressure lowering is safe, but benefit is still hard to prove.
Pohl, MA; Vidt, DG, 1999
)
0.3
" Also, the effectiveness, tolerability, and adverse reactions of these two antihypertensive agents for ISH have not been thoroughly assessed in Chinese."( Comparison of clinical efficacy and adverse effects between extended-release felodipine and slow-release diltiazem in patients with isolated systolic hypertension.
Chern, MS; Lin, FC; Wu, D, 1999
)
0.53
"Sitting blood pressures (BP), heart rate, body weight, adverse reactions, and serum biochemistry were assessed in 70 patients with isolated systolic hypertension (34 treated with felodipine ER and 36 slow-release diltiazem [diltiazem SR] for 10 weeks)."( Comparison of clinical efficacy and adverse effects between extended-release felodipine and slow-release diltiazem in patients with isolated systolic hypertension.
Chern, MS; Lin, FC; Wu, D, 1999
)
0.72
" Overall, these two groups of patients had the same rate of adverse reactions (50."( Comparison of clinical efficacy and adverse effects between extended-release felodipine and slow-release diltiazem in patients with isolated systolic hypertension.
Chern, MS; Lin, FC; Wu, D, 1999
)
0.53
" Drug-related adverse experiences occurred in 30 patients (22."( Efficacy and safety of losartan/hydrochlorothiazide in patients with severe hypertension.
Aurup, P; Goldberg, A; Oparil, S; Snavely, D, 2001
)
0.31
" There was no significant difference between these two drugs in anti-hypertensive effect, heart rate, laboratory measurements or incidence of adverse events."( Efficacy and safety of barnidipine compared with felodipine in the treatment of hypertension in Chinese patients.
Chao, CL; Chien, KL; Lee, TM; Liau, CS,
)
0.39
" No serious adverse events were reported."( Safety and efficacy of therapeutically equivalent doses of sustained-release formulations of isradipine and felodipine.
Ganz, MB; Saska, BA,
)
0.34
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" The main adverse event related to Felodipine was headache, and to Lisinopril was cough."( [Efficacy, safety and tolerance of Felodipine controlled release tablets and Felodipine controlled release tablets associated combination therapy in the treatment of mild to moderate essential hypertension in China].
Chen, YY; Liu, HL; Shen, FR; Sun, NL; Tao, J; Wu, HY; Xiang, XP; Yu, ZQ; Zhang, FC; Zhang, L; Zhang, WZ; Zhao, JA, 2007
)
0.89
"1%) were the most commonly reported clinical adverse experiences in patients treated with losartan."( Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors.
Dunlay, MC; Goldberg, AI; Sweet, CS, 1995
)
0.53
" Activation of PXR has the potential to initiate adverse effects, causing drug-drug interactions, and perturbing normal physiological functions."( QSAR model for human pregnane X receptor (PXR) binding: screening of environmental chemicals and correlations with genotoxicity, endocrine disruption and teratogenicity.
Dybdahl, M; Jónsdóttir, SÓ; Niemelä, JR; Nikolov, NG; Wedebye, EB, 2012
)
0.38
" A typical side effect observed with few agents of this class is dose-dependent cardiotoxicity."( Doxorubicin mediated cardiotoxicity in rats: protective role of felodipine on cardiac indices.
Balaraman, R; Gandhi, H; Mistry, N; Nandania, J; Patel, VB; Patni, N, 2013
)
0.63
" Adverse events occurred at 24."( [Efficacy and safety of aranidipine in Chinese patients with mild-to-moderate essential hypertension].
Chen, L; Jiao, Y; Jin, H; Ke, YN; Li, DY; Liu, MX; Wang, BY; Wang, L; Wang, Y; Yang, HY; Zhao, XL; Zheng, JT, 2013
)
0.39

Pharmacokinetics

Felodipine is a potential perpetrator of pharmacokinetic drug-drug interactions (PK-DDIs) involving cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp) This study aimed to elucidate the impact of SMS on nifedipine/felodipsine treatment.

ExcerptReferenceRelevance
" With increasing age the plasma concentrations and the terminal half-life of felodipine increased, whereas the plasma clearance and the ratio of the AUC of the primary pyridine metabolite to that of unchanged drug decreased."( Felodipine pharmacokinetics and plasma concentration vs effect relationships.
Blychert, E, 1992
)
1.96
" Diazepam plasma concentrations and pharmacokinetic parameters were not affected by the concomitant medication with felodipine."( The effects of felodipine on the pharmacokinetics of diazepam.
de la Rey, N; Hundt, HK; Luus, HG; Meyer, BH; Müller, FO; Röthig, HJ, 1992
)
0.85
"The effect of drinking grapefruit juice on the acute pharmacokinetic and haemodynamic actions of the dihydropyridine calcium antagonist felodipine given as a 5 mg plain tablet has been studied in nine, healthy, middle-aged males."( Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.
Bailey, D; Bergstrand, R; Edgar, B; Johnsson, G; Regårdh, CG, 1992
)
0.71
" The possibility of an acute pharmacokinetic or pharmacodynamic interaction between the ACE inhibitor ramipril and the calcium antagonist felodipine was examined in 12 normotensive male volunteers."( A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects.
Bainbridge, AD; Lees, KR; MacFadyen, RJ; Reid, JL, 1991
)
0.72
" The mean elimination half-life of 24h together with the extended release formulation of felodipine favours once-daily dosage in patients with hypertension."( Felodipine clinical pharmacokinetics.
Dunselman, PH; Edgar, B, 1991
)
1.95
" The pharmacokinetic characteristics and reduction in diastolic BP were similar to those in hypertensive patients with normal renal function and in uremic patients who were not treated with dialysis."( Pharmacokinetics of felodipine in chronic hemodialysis patients.
Aberg, J; Buur, T; Larsson, R; Regårdh, CG, 1991
)
0.6
" With increasing age the area under the felodipine plasma concentration vs time curve (AUC), the maximum plasma concentration (Cmax), and the terminal elimination half-life of felodipine increased, while the plasma clearance of felodipine decreased."( A population study of the pharmacokinetics of felodipine.
Blychert, E; Edgar, B; Elmfeldt, D; Hedner, T, 1991
)
0.81
" The terminal plasma half-life (t1/2) on day 29 was 22 hours and systemic clearance was 490 mL/min on day 1 and 434 mL/min on day 29 (NS)."( Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function.
Aberg, J; Gelin, A; Karlberg, BE; Larsson, R; Regårdh, CG, 1990
)
0.51
" There was a significant decrease in the maximal plasma concentration and AUC of metoprolol after 28 days of treatment with felodipine, but its elimination half-life was not changed."( Haemodynamic effects and pharmacokinetics of felodipine at rest and during exercise in hypertensive patients treated with metoprolol or atenolol.
Bengtsson-Hasselgren, B; Elmfeldt, D; Moberg, L; Rönn, O, 1989
)
0.74
" The pharmacokinetic data were compared with data from young healthy individuals and hypertensive patients."( Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure.
Dunselman, PH; Edgar, B; Kuntze, CE; Scaf, AH; Wesseling, H, 1989
)
0.6
" The pharmacokinetic parameters of felodipine (Cmax, tmax, t1/2 and AUC), the concentration-response curves for blood pressure lowering effects, the reflex tachycardia, diuretic properties and side-effects profile of felodipine were not significantly altered by indomethacin pretreatment in normal volunteers."( Effect of indomethacin on the pharmacokinetics and pharmacodynamics of felodipine.
Bailey, DG; Bartle, WR; Edgar, B; Hardy, BG; Myers, M, 1988
)
0.78
" The mean elimination half-life of felodipine is approximately 25h."( Clinical pharmacokinetics of felodipine. A summary.
Edgar, B; Lundborg, P; Regårdh, CG, 1987
)
0.84
"This overview presents the pharmacodynamic properties of felodipine as studied in animal experiments with emphasis on results from our laboratory."( Pharmacodynamic properties of felodipine.
Ljung, B; Nordlander, M, 1987
)
0.81
" Cmax (17 nmol/L), Cmin (5 nmol/L) and AUC (82 nmol/L."( Pharmacokinetics and blood pressure effects of felodipine in elderly hypertensive patients. A comparison with young healthy subjects.
Edgar, B; Gabrielsson, M; Landahl, S; Larsson, M; Lernfelt, B; Lundborg, P; Regårdh, CG, 1988
)
0.53
" The absorption characteristics Cmax and Tmax were calculated both for felodipine and digoxin on the different felodipine doses."( Pharmacokinetics of felodipine and effect on digoxin plasma levels in patients with heart failure.
Billing, E; Lundman, T; Moberg, L; Olsson, G; Rehnqvist, N, 1987
)
0.83
" There was at least a 7-day washout period between each pharmacokinetic study day."( Pharmacokinetic interactions between felodipine and metoprolol.
Jack, DB; Kendall, MJ; Laugher, S; Smith, SR; Wilkins, MR, 1987
)
0.55
" Steady-state pharmacokinetic parameters of FEL and its pyridine metabolite were not influenced by the single dose of OXC."( Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine.
Bendoni, L; Gangemi, PF; Menge, GP; Monza, GC; Schwabe, S; Zaccara, G, 1993
)
0.51
"A stereoselective and sensitive method for the determination of the enantiomers of felodipine, a dihydropyridine calcium antagonist, has been developed and the pharmacokinetic profiles of the enantiomers comparatively studied after oral administration to dogs and humans."( Determination of felodipine enantiomers using chiral stationary phase liquid chromatography and gas chromatography/mass spectrometry, and the study of their pharmacokinetic profiles in human and dog.
Itoh, M; Kuriki, T; Ohtake, Y; Sakamoto, T; Tabata, S; Uno, K,
)
0.7
" Pharmacokinetic and haemodynamic data were combined to construct a haemodynamic-pharmacokinetic model."( Relationship of changes in felodipine pharmacokinetics to haemodynamics during chronic oral treatment of congestive heart failure patients.
Dunselman, PH; Scaf, AH; Wesseling, H, 1995
)
0.59
"For cyclosporine, Cmax was increased after combined treatment (16%) compared to cyclosporine alone, but felodipine did not influence other kinetic parameters of cyclosporine."( Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine.
Jensen, JD; Jensen, LW; Madsen, JK; Pedersen, EB, 1996
)
0.73
"A combined single dose of cyclosporine and felodipine in healthy subjects increased the AUC and Cmax of felodipine suggesting a cyclosporine-induced decrease in the first-pass metabolism of felodipine, whereas the AUC of cyclosporine was only slightly increased by felodipine."( Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine.
Jensen, JD; Jensen, LW; Madsen, JK; Pedersen, EB, 1996
)
0.78
" Grapefruit juice drunk simultaneously with and 1, 4, 10 or 24 hours before the drug administration resulted in a 32-99% increase in mean Cmax values of felodipine, relative to concomitant water and felodipine intake."( Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects.
Edgar, B; Johnsson, G; Lundahl, J; Regårdh, CG, 1995
)
0.7
" The in vitro dissociation constant (Kd) of felodipine to the calcium channel in the heart of rats was determined, and was compared to the in vivo dissociation constant (Kd,calc) estimated by the pharmacodynamic analysis of the concentration-effect data in Japanese essential hypertensive patients obtained from literature."( In vitro-in vivo correlation of pharmacodynamics of felodipine in essential hypertensive patients based on an ion-channel binding model.
Iga, T; Kotaki, H; Nakajima, Y; Sawada, Y; Shimada, S; Yamamoto, K, 1996
)
0.81
"Intake of grapefruit juice did not significantly alter the intravenous pharmacokinetics of felodipine compared to control treatment, whereas after oral drug administration it did lead to an increase in the mean AUC and Cmax by 72% and 173%, respectively, and the mean absolute bioavailability was increased by 112%."( Effects of grapefruit juice ingestion--pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men.
Edgar, B; Johnsson, G; Lundahl, J; Regårdh, CG, 1997
)
0.73
" The pharmacokinetic analysis included enantioselective analysis in six subjects."( Bioequivalence, pharmacokinetic and pharmacodynamic response to combined extended release formulations of felodipine and metoprolol in healthy volunteers.
Aberg, J; Abrahamsson, B; Grind, M; Nyberg, G; Olofsson, B, 1997
)
0.51
"Bioequivalence between the fixed combination and the free combination was observed for the two drugs (mean difference 27%) except for a minor deviation regarding Cmax of metoprolol in the elderly."( Bioequivalence, pharmacokinetic and pharmacodynamic response to combined extended release formulations of felodipine and metoprolol in healthy volunteers.
Aberg, J; Abrahamsson, B; Grind, M; Nyberg, G; Olofsson, B, 1997
)
0.51
" Finally, felodipine and metoprolol do not interact on a pharmacokinetic level when administered as the fixed combination."( Bioequivalence, pharmacokinetic and pharmacodynamic response to combined extended release formulations of felodipine and metoprolol in healthy volunteers.
Aberg, J; Abrahamsson, B; Grind, M; Nyberg, G; Olofsson, B, 1997
)
0.91
" Significant differences were found between all principal pharmacokinetic variables, when comparing the 2 treatments after both single and repeated dosing."( Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients.
Jacobsen, IA; Videbaek, LM, 1997
)
0.54
" Neither AUC nor trough levels of FEL and AML were significantly influenced by transit times, nor was Cmax after any of the three treatments."( The pharmacokinetics of extended-release formulations of calcium antagonists and of amlodipine in subjects with different gastrointestinal transit times.
Laufen, H; Riedel, KD; Scharpf, F; Schumacher, T; Yeates, R; Zimmermann, T, 1999
)
0.3
"Several statistical regression models and artificial neural networks were used to predict the hepatic drug clearance in humans from in vitro (hepatocyte) and in vivo pharmacokinetic data and to identify the most predictive models for this purpose."( Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
Coassolo, P; Lavé, T; Schneider, G, 1999
)
0.3
" Methods Using felodipine as a model drug, we constructed a pharmacokinetic model based on irreversible inhibition of intestinal cytochrome P450 3A4 (CYP3A4) by GFJ."( Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model.
Higuchi, S; Kuroda, K; Matsuo, H; Murakami, H; Ohnishi, A; Sata, H; Sawada, Y; Takanaga, H; Urae, A, 2000
)
0.95
" A secondary aim was to relate the efficacy of the free and fixed combinations with pharmacokinetic profiles."( The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients.
Elliott, HL; Hosie, J; MacDonald, TM; McLay, JS, 2000
)
0.53
" Pharmacokinetic evaluation revealed identical plasma concentration-time curves for felodipine given as the free or fixed combination."( The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients.
Elliott, HL; Hosie, J; MacDonald, TM; McLay, JS, 2000
)
0.75
" The pharmacokinetic parameters of felodipine in ten men were investigated by this method."( [Determination of felodipine concentration in human plasma by GC-ECD and study of its pharmacokinetics].
Dai, X; Yang, L; Yuan, Y, 1998
)
0.91
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
"The aim was to study the pharmacodynamic interactions and safety of the co-administration of the calcium sensitizer levosimendan and the calcium antagonist felodipine in patients with coronary heart disease (CHD) and with normal ejection fraction (EF)."( Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease.
Akkila, J; Antila, S; Eha, J; Heinpalu, M; Lehtonen, L; Loogna, I; Mesikepp, A; Planken, U; Põder, P,
)
0.58
"No clinically significant pharmacodynamic interactions between levosimendan and felodipine were seen."( Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease.
Akkila, J; Antila, S; Eha, J; Heinpalu, M; Lehtonen, L; Loogna, I; Mesikepp, A; Planken, U; Põder, P,
)
0.61
" Recent studies with a 103-compound dataset suggested that scaling from monkey pharmacokinetic data tended to be the most accurate method for predicting human clearance."( Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
Evans, CA; Jolivette, LJ; Nagilla, R; Ward, KW, 2006
)
0.33
" The established method has been successfully applied to a pharmacokinetic study of gambogic acid in dogs."( Determination of gambogic acid in dog plasma by high-performance liquid chromatography for a pharmacokinetic study.
Hao, K; Liu, XQ; Wang, GJ; Zhao, XP, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" The Cmax and AUC of DTZ were decreased significantly in the presence of multiple dose treatment of GFJ."( Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens.
Avery, BA; Boddu, SP; Kuma, SV; Potharaju, S; Rajak, S; Repka, MA; Varanasi, VS; Veeraraghavan, S; Yamsani, MR, 2009
)
0.35
" Although a lot of clinical research has been performed on the pharmacokinetic variations of felodipine, there has been no adequate systematic study."( Publication bias on clinical studies of pharmacokinetic interactions between felodipine and grapefruit juice.
Mohri, K; Takeuchi, T; Uesawa, Y, 2010
)
0.81
" This report discusses a clinically relevant pharmacokinetic CYP3A4 drug-drug interaction between sorafenib and felodipine in an 80-year-old Caucasian patient with HCC."( Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Tod, M, 2011
)
0.81
" The method was successfully applied for pharmacokinetic study of pioglitazone and felodipine from bioadhesive buccal tablet after buccal administration to pigs."( Development of a high-performance liquid chromatography method for simultaneous determination of pioglitazone and felodipine in pig serum: application to pharmacokinetic study.
Gannu, R; Palem, CR; Yamsani, MR; Yamsani, SK; Yamsani, VV, 2011
)
0.8
" This is a retrospective review of five felodipine pharmacokinetic studies completed in Taiwan."( Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review.
Hsiao, CL; Hsu, KY; Wu, YC, 2011
)
0.96
" The validated assay was applied to a pharmacokinetic study in rats."( Validated LC-ESI-MS/MS method for simultaneous quantitation of felodipine and metoprolol in rat plasma: application to a pharmacokinetic study in rats.
Kallem, RR; Ramesh, M; Seshagirirao, JV, 2013
)
0.63
"To evaluate felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions (PK-DDIs) involving cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp)."( Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
Doogue, MP; Miners, JO; Polasek, TM; Rowland, A; Snyder, BD, 2014
)
1.14
"A randomized, single-dose, crossover study assessed hemodynamic and pharmacokinetic effects following 2 days without coffee and caffeine-containing foods."( Coffee-Antihypertensive Drug Interaction: A Hemodynamic and Pharmacokinetic Study With Felodipine.
Arnold, JM; Bailey, DG; Dresser, GK; Freeman, DJ; Urquhart, BL, 2016
)
0.66
" Caffeine and felodipine pharmacokinetics were similar for coffee and felodipine given alone or in combination indicating an interaction having a pharmacodynamic basis."( Coffee-Antihypertensive Drug Interaction: A Hemodynamic and Pharmacokinetic Study With Felodipine.
Arnold, JM; Bailey, DG; Dresser, GK; Freeman, DJ; Urquhart, BL, 2016
)
1.02
"A phase I, open-label, single-dose, pharmacokinetic study."( Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study.
Asher, L; Bailey, DG; Chretien, ML; Dresser, GK; Driman, D; Gregor, J; Parfitt, J, 2020
)
0.56
" This impelled us to improve its solubility, bioavailability, and pharmacodynamic properties through the Nanocrystal (NC) approach."( Appraisal of Felodipine Nanocrystals for Solubility Enhancement and Pharmacodynamic Parameters on Cadmium Chloride Induced Hypertension in Rats.
Maurya, P; Pandey, P; Saraf, SA; Singh, S; Sonkar, A, 2022
)
1.09
"The crystalline nature and improved solubility of FDP-NC improve the dissolution profile and pharmacodynamic data."( Appraisal of Felodipine Nanocrystals for Solubility Enhancement and Pharmacodynamic Parameters on Cadmium Chloride Induced Hypertension in Rats.
Maurya, P; Pandey, P; Saraf, SA; Singh, S; Sonkar, A, 2022
)
1.09
" This study aimed to elucidate the impact of SMS on nifedipine/felodipine treatment by the findings from rat pharmacokinetic study of nifedipine to the retrospective cohort study of patients with hypertension."( Effect of repeated Shengmai-San administration on nifedipine pharmacokinetics and the risk/benefit under co-treatment.
Chen, WC; Chia-Hui Tan, E; Chiang, TY; Shen, CC; Ueng, YF; Wang, HJ, 2022
)
0.96
" A physiologically-based pharmacokinetic (PBPK) population for different severities of CeD was developed."( Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug.
Bloomer, J; Mudunuru, J; Nimavardi, A; Salem, F; Taskar, KS; Tompson, D; Turner, DB, 2023
)
1.12

Compound-Compound Interactions

Felodipine was given to 58 hypertensive patients in combination with an adrenergic beta-receptor antagonist and a diuretic agent. During long-term therapy, tolerance was good, and felodipsine seems to be a safe and efficient antihypertensive agent.

ExcerptReferenceRelevance
" Altogether, 251 hypertensive patients with a diastolic blood pressure greater than 95 mm Hg after 4 weeks of treatment with placebo in combination with metoprolol CR 100 mg were randomized to four parallel groups."( Optimal felodipine dose when combined with metoprolol in arterial hypertension: a Swedish multicenter study within primary health care. Swedish General Practitioner Felodipine Study Group.
Bengtsson, C; Brun, J; Fröberg, L; Kronmann, P; Olsson, LB; Scherstén, B; Skoog, P; Tibblin, G; Tygesen, G, 1990
)
0.71
" During long-term therapy, tolerance was good, and felodipine seems to be a safe and efficient antihypertensive agent in combination with a beta-blocker and a diuretic in patients whose hypertension is not adequately controlled on standard triple therapy."( Antihypertensive effects and pharmacokinetics of felodipine combined with a beta-blocker and a diuretic.
Elmfeldt, D; Hedner, T; Sjögren, E, 1987
)
0.78
"Felodipine, a new dihydropyridine, was given to 58 hypertensive patients in combination with an adrenergic beta-receptor antagonist and a diuretic agent."( Long term experience of felodipine in combination with beta-blockade and diuretics in refractory hypertension.
Collste, P; Danielsson, M; Elmfeldt, D; Feleke, E; Gelin, A; Hedner, T; Rydén, L, 1985
)
2.02
"075 mg/kg) of felodipine in combination with the beta-blocker and diuretic."( Felodipine in combination with a beta-blocker and a diuretic in chronic treatment of patients with refractory primary hypertension.
Andersson, OK; Granérus, G; Hedner, T, 1987
)
2.08
"Understanding the potential for cytochrome P450-mediated drug-drug interactions (DDIs) is a critical step in the drug discovery process."( Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation.
Foti, RS; Rock, DA; Wahlstrom, JL; Wienkers, LC, 2010
)
0.36
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"To explore the effect of puerarin combined with felodipine on the mRNA and protein expression of apelin and APJ in renal tissue of renovascular hypertensive rat."( [Effect of puerarin combined with felodipine on mRNA and protein expression of apelin and APJ in renovascular hypertensive rat].
Bai, S; Chen, L; Ding, BP; Huang, ZG; Wang, JT, 2013
)
0.92
"The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker."( The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study.
Chen, W; Fang, H; Liu, X; Xu, W, 2014
)
0.4
"The result showed that the effective rate of one year antihypertensive treatment of arotinolol combined with nifedipine was 51 of 53, significantly effective (p < 0."( The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study.
Chen, W; Fang, H; Liu, X; Xu, W, 2014
)
0.4
"The therapy approached of arotinolol combined with nifedipine or amlodipine could be effective and well-tolerated, and they can be used as the better chosen antihypertensive drug."( The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study.
Chen, W; Fang, H; Liu, X; Xu, W, 2014
)
0.4
"To evaluate felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions (PK-DDIs) involving cytochrome P450 (CYP) enzymes and P-glycoprotein (P-gp)."( Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
Doogue, MP; Miners, JO; Polasek, TM; Rowland, A; Snyder, BD, 2014
)
1.14
" While the drug-drug interaction potential between flavonoids and co-ingested drugs still remain an issue, opportunities exist for the combination of flavonoids with suitable anti-cancer drugs to enhance the bioavailability of anti-cancer drugs and thereby reduce the dose size of the anti-cancer drugs and improve its therapeutic index."( Recent trends in preclinical drug-drug interaction studies of flavonoids--Review of case studies, issues and perspectives.
Srinivas, NR, 2015
)
0.42

Bioavailability

Felodipine (FLD) is a dihydropyridine calcium channel blocker with excellent antihypertensive effect. It is poorly soluble and undergoes extensive hepatic metabolism, which lead to poor oral bioavailability (about 15%) and limit its clinic application.

ExcerptReferenceRelevance
" The time to maximum plasma felodipine concentration, the bioavailability and the volume of distribution were not consistently influenced by age."( Felodipine pharmacokinetics and plasma concentration vs effect relationships.
Blychert, E, 1992
)
2.02
" bioavailability of the dihydropyridine calcium antagonists nifedipine and felodipine."( Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice.
Edgar, B; Eriksson, UG; Lundahl, J; Miniscalco, A; Regårdh, CG, 1992
)
0.51
" The mean felodipine bioavailability with grapefruit juice was 284 (range 164-469)% of that with water."( Interaction of citrus juices with felodipine and nifedipine.
Arnold, JM; Bailey, DG; Munoz, C; Spence, JD, 1991
)
0.96
" In the rat, dog, and human, the bioavailability of an oral dose is about 15% because of high first-pass metabolism."( Stereoselective metabolism of felodipine in liver microsomes from rat, dog, and human.
Bäärnhielm, C; Eriksson, UG; Lundahl, J; Regårdh, CG,
)
0.42
" The absolute bioavailability of felodipine ER was 22%."( Plasma concentration-effect relationships of intravenous and extended-release oral felodipine in hypertensive patients.
Blychert, E; Dahlöf, C; Elmfeldt, D; Hedner, T, 1990
)
0.79
" A pronounced first-pass metabolism results in a bioavailability of 15%, irrespective of the oral formulation used."( Felodipine clinical pharmacokinetics.
Dunselman, PH; Edgar, B, 1991
)
1.72
" After oral administration the bioavailability of (R)-felodipine was slightly higher than that of (S)-felodipine in two of the dogs, presumably due to a lower first-pass extraction of the (R)-enantiomer, while no difference was observed in the other two dogs."( Pharmacokinetics of the enantiomers of felodipine in the dog after oral and intravenous administration of a pseudoracemic mixture.
Eriksson, UG; Hoffmann, KJ; Regårdh, CG; Simonsson, R, 1991
)
0.8
" The bioavailability and steady state volume of distribution and the time to Cmax were not consistently influenced by age."( A population study of the pharmacokinetics of felodipine.
Blychert, E; Edgar, B; Elmfeldt, D; Hedner, T, 1991
)
0.54
" The bioavailability of the oral dose on day 1 and day 29 was 13% and 12."( Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function.
Aberg, J; Gelin, A; Karlberg, BE; Larsson, R; Regårdh, CG, 1990
)
0.51
" The rate of absorption increased in the order extended-release tablets, conventional tablets, solution."( Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets.
Blychert, E; Edgar, B; Lidman, K; Wingstrand, K, 1990
)
0.5
" Felodipine bioavailability was not influenced by ethanol."( Ethanol enhances the hemodynamic effects of felodipine.
Arnold, JM; Bailey, DG; Bayliff, CD; Edgar, B; Spence, JD, 1989
)
1.45
" After oral therapy, significant correlations were found between cardiac output and AUC and systemic bioavailability (F)."( Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure.
Dunselman, PH; Edgar, B; Kuntze, CE; Scaf, AH; Wesseling, H, 1989
)
0.6
"Felodipine is a dihydropyridine calcium antagonist, structurally related to nifedipine, which undergoes extensive first-pass hepatic metabolism and normally has an oral bioavailability of 15%."( Reduced felodipine bioavailability in patients taking anticonvulsants.
Capewell, S; Critchley, JA; Freestone, S; Pottage, A; Prescott, LF, 1988
)
2.15
" Oral bioavailability approached 100%, and hemodynamic responses were gradual in onset and long-lasting in effect."( Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
Arrowsmith, JE; Blackburn, KJ; Burges, RA; Campbell, SF; Cross, PE; Gardiner, DG; Stubbs, JK, 1986
)
0.27
"001) was observed only in patients with a high plasma felodipine level, which may have been caused by changes in the absorption rate in those patients."( Digoxin-felodipine interaction in patients with congestive heart failure.
Dunselman, PH; Kuntze, CE; Lie, KI; Scaf, AH; Wesseling, H, 1988
)
0.96
" The bioavailability is constant within the dose interval of 5 to 40mg orally."( Clinical pharmacokinetics of felodipine. A summary.
Edgar, B; Lundborg, P; Regårdh, CG, 1987
)
0.56
" These tablets were also tested in a bioavailability study together with an oral solution."( Evaluation of solubilizers in the drug release testing of hydrophilic matrix extended-release tablets of felodipine.
Abrahamsson, B; Johansson, D; Torstensson, A; Wingstrand, K, 1994
)
0.5
" The absorption rate of felodipine was related to erosion of the hydrophilic matrix tablet."( Absorption, gastrointestinal transit, and tablet erosion of felodipine extended-release (ER) tablets.
Abrahamsson, B; Alpsten, M; Hugosson, M; Jonsson, UE; Sundgren, M; Svenheden, A; Tölli, J, 1993
)
0.84
" This reduction in FEL bioavailability is much smaller than that observed after co-administration of carbamazepine (CBZ) (i."( Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine.
Bendoni, L; Gangemi, PF; Menge, GP; Monza, GC; Schwabe, S; Zaccara, G, 1993
)
0.51
" The interaction could not be predicted from baseline pharmacokinetics with water and did not result in more consistent bioavailability among individuals."( Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin.
Arnold, JM; Bailey, DG; Munoz, C; Spence, JD, 1993
)
0.62
"Intake of grapefruit juice did not significantly alter the intravenous pharmacokinetics of felodipine compared to control treatment, whereas after oral drug administration it did lead to an increase in the mean AUC and Cmax by 72% and 173%, respectively, and the mean absolute bioavailability was increased by 112%."( Effects of grapefruit juice ingestion--pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men.
Edgar, B; Johnsson, G; Lundahl, J; Regårdh, CG, 1997
)
0.73
"Grapefruit juice enhances the effect of some commonly used medications by increasing their bioavailability via the selective down-regulation of a specific subfamily of the cytochrome P450 enzyme system in the small intestine."( How grapefruit juice potentiates drug bioavailability.
Feldman, EB, 1997
)
0.3
"The novel finding that grapefruit juice can markedly augment oral drug bioavailability was based on an unexpected observation from an interaction study between the dihydropyridine calcium channel antagonist, felodipine, and ethanol in which grapefruit juice was used to mask the taste of the ethanol."( Grapefruit juice-drug interactions.
Arnold, O; Bailey, DG; Malcolm, J; Spence, JD, 1998
)
0.49
" The variable effect with the particulate fraction may result from erratic bioavailability of unidentified primary active substances."( Grapefruit juice-felodipine interaction: effect of naringin and 6',7'-dihydroxybergamottin in humans.
Bailey, DG; Bend, JR; Freeman, DJ; Kreeft, JH; Munoz, C, 1998
)
0.64
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"Grapefruit juice can increase the oral bioavailability of a broad range of medications."( Grapefruit juice--felodipine interaction in the elderly.
Bailey, DG; Carruthers, SG; Dresser, GK, 2000
)
0.64
" However, the particle size seems to have a much more important influence on the bioavailability of felodipine than the hydrodynamics per se."( Influence of hydrodynamics and particle size on the absorption of felodipine in labradors.
Abrahamsson, B; Diebold, SM; Dressman, JB; Kostewicz, E; Polentarutti, BI; Scholz, A; Ungell, AL, 2002
)
0.77
"Drug efflux by intestinal P-glycoprotein (P-gp) is known to decrease the oral bioavailability of many CYP3A4 substrates."( Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.
Benet, LZ; Cummins, CL; Jacobsen, W, 2002
)
0.31
"Our study was designed to determine the effect of peppermint oil and ascorbyl palmitate on cytochrome P4503A4 (CYP3A4) activity in vitro and oral bioavailability of felodipine in humans."( Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo.
Bailey, DG; Dresser, GK; Wacher, V; Wong, HT; Wong, S, 2002
)
0.51
" Grapefruit juice increased the oral bioavailability of felodipine by inhibition of CYP3A4-mediated presystemic drug metabolism."( Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo.
Bailey, DG; Dresser, GK; Wacher, V; Wong, HT; Wong, S, 2002
)
0.56
"Bergamottin enhanced the oral bioavailability of felodipine and may cause a clinically relevant drug interaction in susceptible individuals."( Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans.
Bailey, DG; Cillié, D; Cohen, L; Dijkstra, HP; Goosen, TC; He, K; Hollenberg, PF; Rheeders, M; Williams, JA; Woster, PM; Yu, C, 2004
)
0.83
"Crystallization of drugs formulated in the amorphous form may lead to reduced apparent solubility, decreased rate of dissolution and bioavailability and compromise the physical integrity of the solid dosage form."( Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility.
Marsac, PJ; Shamblin, SL; Taylor, LS, 2006
)
0.33
"To measure the solubility of four drugs in human gastric aspirates, canine gastric aspirates (CGF) and simulated gastric fluids in order to propose a medium for estimating intragastric drug solubility relevant to a bioavailability study in the fasted state."( Estimation of intragastric solubility of drugs: in what medium?
Kalantzi, L; Pastelli, E; Psachoulias, D; Reppas, C; Vertzoni, M, 2007
)
0.34
"6 is comparatively the most efficient way to get an estimate of drug solubility in the fasting gastric contents during a bioavailability study."( Estimation of intragastric solubility of drugs: in what medium?
Kalantzi, L; Pastelli, E; Psachoulias, D; Reppas, C; Vertzoni, M, 2007
)
0.34
"To prepare transdermal drug delivery system (TDDS) of felodipine and metoprolol and to study its pharmaceutical characteristics, pharmacokinetics and bioavailability in rabbits, an HPLC assay was established for the simultaneous determination of felodipine and metoprolol in the permeation receptor and patch."( [Preparation of transdermal drug delivery system of felodipine-metoprolol and its bioavailability in rabbits].
Fu, GY; Liu, ZY; Wang, R; Wang, WG; Yun, LH, 2007
)
0.84
"Amorphous solid dispersions are used as a strategy to improve the bioavailability of poorly water-soluble compounds."( Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine.
Alonzo, DE; Handa, T; Konno, H; Taylor, LS, 2008
)
0.57
" As for these interactions, most reports have focused on the elevation of drug bioavailability by GFJ, but a few recent reports have indicated that GFJ reduced the absorption of drugs not metabolized by cytochrome P450 (CYP)."( Effect of grapefruit juice in relation to human pharmacokinetic study.
Uno, T; Yasui-Furukori, N, 2006
)
0.33
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The purpose of the present research was to develop bioadhesive buccal tablets for Felodipine (FDP) and Pioglitazone (PIO), low bioavailability drugs, in a combined dosage form for the management of diabetes and hypertension."( Development of bioadhesive buccal tablets for felodipine and pioglitazone in combined dosage form: in vitro, ex vivo, and in vivo characterization.
Gannu, R; Palem, CR; Yamsani, MR; Yamsani, SK; Yamsani, VV, 2011
)
0.85
"Amorphous solid dispersions (ASDs) are widely utilized in the pharmaceutical industry for bioavailability enhancement of low solubility drugs."( Dissolution and precipitation behavior of amorphous solid dispersions.
Alonzo, DE; Gao, Y; Mo, H; Taylor, LS; Zhang, GGZ; Zhou, D, 2011
)
0.37
"Stabilization of amorphous state is a focal area for formulators to reap benefits related with solubility and consequently bioavailability of poorly soluble drugs."( Moringa coagulant as a stabilizer for amorphous solids: Part I.
Bhende, S; Jadhav, N, 2012
)
0.38
"Amorphous drug-polymer solid dispersions have the potential to enhance the dissolution performance and thus bioavailability of BCS class II drug compounds."( Construction of drug-polymer thermodynamic phase diagrams using Flory-Huggins interaction theory: identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions.
Andrews, GP; Booth, J; Jones, DS; Li, S; Meehan, E; Tian, Y, 2013
)
0.39
"In order to improve the in vitro dissolution rate and in vivo oral bioavailability of the poorly water soluble drug, felodipine (FELO), the wet-milling process was employed involving co-grinding with HPMC E5 and the in vitro release rate as investigated."( In vitro/in vivo evaluation of felodipine micropowders prepared by the wet-milling process combined with different solidification methods.
Cai, C; Li, S; Meng, J; Tang, X; Weng, Y; Xu, H; Yao, Q; Zhang, L, 2014
)
0.9
" The findings revealed that particle size reduction can influence felodipine absorption in gastrointestinal tract and nanosuspension can enhance oral bioavailability of felodipine in rats."( Preparation and in vitro/in vivo evaluation of felodipine nanosuspension.
Das, MK; Sahu, BP, 2014
)
0.9
"Objective of the present investigation was to enhance the bioavailability of felodipine by targeting the M cells of Peyer's patches using PLGA nanoparticles (NPs)."( Improvement in antihypertensive and antianginal effects of felodipine by enhanced absorption from PLGA nanoparticles optimized by factorial design.
Joshi, G; Sawant, K; Shah, U, 2014
)
0.87
"To compare the properties of solid dispersions of felodipine for oral bioavailability enhancement using two different polymers, polyvinylpyrrolidone (PVP) and hydroxypropyl methylcellulose acetate succinate (HPMCAS), by hot-melt extrusion (HME) and spray drying."( A comparative study of the effect of spray drying and hot-melt extrusion on the properties of amorphous solid dispersions containing felodipine.
Kelly, A; Mahmah, O; Paradkar, A; Tabbakh, R, 2014
)
0.86
"Solid dispersion technology has been widely explored to improve the solubility and bioavailability of poorly water-soluble compounds."( Investigation of phase diagrams and physical stability of drug-polymer solid dispersions.
Gryczke, A; Jo, S; Kolter, K; Langley, N; Lu, J; Majumdar, S; Repka, MA; Shah, S, 2015
)
0.42
"Overcoming the low oral bioavailability of many drugs due to their poor aqueous solubility is one of the major challenges in the pharmaceutical industry."( Hydroxypropyl cellulose stabilizes amorphous solid dispersions of the poorly water soluble drug felodipine.
Cote, C; Malekar, SA; Sarode, AL; Worthen, DR, 2014
)
0.62
"8-fold, the bioavailability was increased 18% and the maximum plasma concentration reduced by 25%."( Preparation of a push-pull osmotic pump of felodipine solubilized by mesoporous silica nanoparticles with a core-shell structure.
Hao, Y; Liu, C; Liu, Y; Wu, C; Zhao, Y; Zhao, Z, 2014
)
0.67
"The novel self-microemulsifying (SME) tablets were developed to enhance the oral bioavailability of a poor water-soluble drug felodipine (FDP)."( Enhanced oral bioavailability of felodipine by novel solid self-microemulsifying tablets.
He, Z; Jing, B; Tang, S; Wang, Z; Yang, R; Zhao, J; Zheng, X, 2016
)
0.92
" While the drug-drug interaction potential between flavonoids and co-ingested drugs still remain an issue, opportunities exist for the combination of flavonoids with suitable anti-cancer drugs to enhance the bioavailability of anti-cancer drugs and thereby reduce the dose size of the anti-cancer drugs and improve its therapeutic index."( Recent trends in preclinical drug-drug interaction studies of flavonoids--Review of case studies, issues and perspectives.
Srinivas, NR, 2015
)
0.42
"The bioavailability of orally administered drugs that exhibit poor aqueous solubility can be enhanced with the use of supersaturating dosage forms."( Influence of Polymers on the Crystal Growth Rate of Felodipine: Correlating Adsorbed Polymer Surface Coverage to Solution Crystal Growth Inhibition.
Beaudoin, SP; Schram, CJ; Taylor, LS, 2015
)
0.67
" As a pharmaceutical adjuvant, 3DOMTS was used to improve the dissolution rate and oral relative bioavailability of water-insoluble drugs."( Development of a novel starch with a three-dimensional ordered macroporous structure for improving the dissolution rate of felodipine.
Hao, Y; Jiang, J; Ma, C; Qiu, Y; Wu, C; Xu, J; Yu, T; Zhao, Y; Zhao, Z; Zhou, B, 2016
)
0.64
" The similar absorption rate between felodipine and metoprolol in beagles was also obtained by this osmotic pump formulation."( Synchronous delivery of felodipine and metoprolol tartrate using monolithic osmotic pump technology.
Di, Z; Li, Y; Li, Z; Liu, N; Liu, Y; Mei, X; Yan, K; Yang, Y; Yang, Z; Yu, F; Zhang, H; Zhao, S, 2016
)
1.01
"Poor oral bioavailability is the single most important challenge in drug delivery."( Enhancement of the Oral Bioavailability of Felodipine Employing 8-Arm-Poly(Ethylene Glycol): In Vivo, In Vitro and In Silico Evaluation.
Bijukumar, D; Choonara, YE; du Toit, LC; Fasinu, P; Khan, RA; Kumar, P; Pillay, V, 2017
)
0.72
"Understanding drug-polymer molecular interactions, their miscibility, supersaturation potential, and the effects of water uptake may be invaluable for selecting amorphous polymer dispersions that can maximize the oral bioavailability of poorly water-soluble drugs."( Molecular Dynamics Simulation of Amorphous Hydroxypropylmethylcellulose and Its Mixtures With Felodipine and Water.
Anderson, BD; Xiang, TX, 2017
)
0.67
" Significant enhancement of bioavailability was observed in eutectics (3."( Multicomponent solid forms of felodipine: preparation, characterisation, physicochemical and in-vivo studies.
Chadha, R; Haneef, J; Sharma, M, 2017
)
0.74
"The oral bioavailability of felodipine very low, nearly just 15% due to its limited solubility and high first pass metabolism."( Formulation, evaluation and optimization of the felodipine nanosuspension to be used for direct compression to tablet for in vitro dissolution enhancement.
Chavda, J; Makwana, J; Mori, D; Parmar, R; Patel, K, 2016
)
0.98
" The high throughput, accurate and sensitive method for FDP and MPL was validated and applied to the bioavailability research of FDP and MPL in beagle dogs."( Simultaneous Determination of Felodipine and Metoprolol in Beagle Dog Plasma by Online SPE-LC-MS/MS and Its Application in a Pharmacokinetic Study.
Chen, M; Li, Y; Liu, Y; Mei, L; Mei, X; Xie, X; Yang, Y; Yu, F; Zhou, J, 2017
)
0.74
"Felodipine has a very low bioavailability due to first-pass metabolism."( Dry Gel Containing Optimized Felodipine-Loaded Transferosomes: a Promising Transdermal Delivery System to Enhance Drug Bioavailability.
Aboul-Einien, MH; El Taweel, MM; Kassem, MA, 2018
)
2.21
" This means that it is possible the product differs both compositionally and structurally between the time of manufacture and the time it is taken by the patient, leading to poor bioavailability and so ultimately the shelf-life of the product has to be reduced."( Modelling phase separation in amorphous solid dispersions.
McGinty, S; Meere, M; Pontrelli, G, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" In conclusion, STC/Soluplus SHNPs via ASBT are a potential strategy for enhancing the oral bioavailability of poorly water-soluble drugs."( Bile acid transporter mediated STC/Soluplus self-assembled hybrid nanoparticles for enhancing the oral drug bioavailability.
Cui, D; Wang, J; Wei, Q; Xiong, S; Xu, J; Zhang, S, 2020
)
0.56
" These patients are hypothesised to have greater systemic concentrations of felodipine, a drug which normally has low oral bioavailability secondary to intestinal CYP3A4-mediated metabolism."( Severity of coeliac disease and clinical management study when using a CYP3A4 metabolised medication: a phase I pharmacokinetic study.
Asher, L; Bailey, DG; Chretien, ML; Dresser, GK; Driman, D; Gregor, J; Parfitt, J, 2020
)
0.79
"Felodipine (FLD), a dihydropyridine calcium channel blocker with excellent antihypertensive effect, is poorly soluble and undergoes extensive hepatic metabolism, which lead to poor oral bioavailability (about 15%) and limit its clinic application."( Enhanced Oral Bioavailability of Felodipine from Solid Lipid Nanoparticles Prepared Through Effervescent Dispersion Technique.
Bai, Y; He, Y; Hu, M; Pi, C; Wei, Y; Yang, S; Zhan, C; Zhao, L; Zuo, Y, 2020
)
2.28
" Noteworthily, current researches around co-amorphous system (CAS) are mostly focused on preparation and characterization of these systems, but more detailed investigations of their supersaturation ("spring-parachute" process), stability, in vivo bioavailability and molecular mechanisms are inadequate and need to be clarified."( "Felodipine-indomethacin" co-amorphous supersaturating drug delivery systems: "Spring-parachute" process, stability, in vivo bioavailability, and underlying molecular mechanisms.
Cai, JH; Cui, BJ; Feng, B; Guan, J; Hao, CY; Jin, Y; Li, YW; Qi, XR; Shi, NQ; Wang, D; Zhang, HM; Zhu, HY, 2021
)
1.53
"Amorphization is a powerful approach for improving the aqueous solubility and bioavailability of poorly water-soluble compounds."( Influence of the crystallization tendencies of pharmaceutical glasses on the applicability of the Adam-Gibbs-Vogel and Vogel-Tammann-Fulcher equations in the prediction of their long-term physical stability.
Kawakami, K; Miyazaki, T; Mizoguchi, R; Yamaguchi, K, 2022
)
0.72
" However, the underlying mechanisms of the effects of inhomogeneous phase on the dissolution characteristics as well as the bioavailability of ASDs are still unclear."( Inhomogeneous Phase Significantly Reduces Oral Bioavailability of Felodipine/PVPVA Amorphous Solid Dispersion.
Chen, Y; Dong, S; Gao, D; Zhou, X; Zhu, D, 2023
)
1.15

Dosage Studied

Felodipine taken with grapefruit juice resulted in a greater change in blood pressure measured in the morning 3 h after dosing than did water. Blood pressure was significantly reduced during the dosage interval of felodipsine (12 h) No dosage adjustment of felidipine seems to be necessary in patients with hypertension and renal impairment.

ExcerptRelevanceReference
" During chronic therapy, at the end of the dosing interval (12 hours), significant decreases in BP persisted with minimal changes in the other variables."( Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy.
Holliwell, DL; Leenen, FH, 1992
)
0.58
" For a majority of hypertensive patients the adequacy of blood pressure control and the simplicity of once daily dosing will favour the extended release tablet given once daily."( Twenty-four hour blood pressure profiles in hypertensive patients following various formulations and dosage regimens of felodipine.
Blychert, E; Frisén, M; Karlsson, O; Rydén, L, 1992
)
0.49
" The higher plasma concentrations of felodipine taken with grapefruit juice resulted in a greater change in blood pressure measured in the morning 3 h after dosing (-9%) than did water (0%)."( Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance.
Bailey, D; Bergstrand, R; Edgar, B; Johnsson, G; Regårdh, CG, 1992
)
0.78
"5 h after dosing with HCTZ, which was not significantly lower."( Comparison of once daily felodipine 10 mg ER and hydrochlorothiazide 25 mg in the treatment of mild to moderate hypertension.
Binner, L; Hehr, R; Hombach, V; Koenig, W; Rosenthal, J; Sund, M, 1991
)
0.58
" Although some patients may be controlled throughout the entire dosing interval when felodipine is administered bid, many patients will require more frequent dosing to obtain adequate BP control."( Felodipine: a new dihydropyridine calcium-channel antagonist.
Lopez, LM; Yedinak, KC, 1991
)
1.95
" The variability in plasma concentrations is wide, and individualization of the dosage is recommended."( Felodipine clinical pharmacokinetics.
Dunselman, PH; Edgar, B, 1991
)
1.72
" All measurements were performed at the end of the dosing interval."( Hemodynamic interactions between diuretics and calcium antagonists in the treatment of hypertensive patients.
Cavallotti, G; de Divitiis, O; Di Somma, S; Liguori, V; Petitto, M; Savonitto, S, 1990
)
0.28
" No dosage adjustment of felodipine seems to be necessary in patients with hypertension and renal impairment."( Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function.
Aberg, J; Gelin, A; Karlberg, BE; Larsson, R; Regårdh, CG, 1990
)
0.81
" The dosage of felodipine or nifedipine was doubled if seated diastolic blood pressure exceeded 95 mmHg, 2 or 4 weeks after randomisation."( Control of blood pressure in hypertensive patients with felodipine extended release or nifedipine retard.
Littler, WA, 1990
)
0.88
" As from a solution, felodipine was completely absorbed from the two solid dosage forms."( Plasma concentration profiles and antihypertensive effect of conventional and extended-release felodipine tablets.
Blychert, E; Edgar, B; Lidman, K; Wingstrand, K, 1990
)
0.82
" Compared with the placebo, felodipine lowered blood pressure during a 12 h interval, which supports a twice-daily dosage in clinical practice."( Antihypertensive effects and pharmacokinetics of felodipine combined with a beta-blocker and a diuretic.
Elmfeldt, D; Hedner, T; Sjögren, E, 1987
)
0.82
" In addition, verapamil shifted the dose-response curves for both 5-HT and PE to the right in parallel, indicative of competitive antagonism."( Studies on the site of the interaction between alpha 1-adrenoceptors and 5-HT2 receptors in rat tail arteries.
Marwood, JF, 1988
)
0.27
" Thus, felodipine in modest therapeutic dosage decreases the plasma levels of B-TG and PF-4, indicating an inhibitory effect on platelet on release."( Effect of felodipine, a new calcium channel antagonist, on platelet function and fibrinolytic activity at rest and after exercise.
Sengeløv, H; Winther, K, 1989
)
1.13
" The dosage of felodipine was increased from 5 mg twice daily to 10 mg twice daily after two weeks."( The effects of treatment with felodipine as a single agent in coronary artery disease.
Chan-Wah-Hak, NS; Jennings, K; Metcalfe, MJ, 1989
)
0.92
" Thus, it is advisable to start felodipine treatment at a low dosage in patients with congestive heart failure."( Pharmacokinetics of felodipine after intravenous and chronic oral administration in patients with congestive heart failure.
Dunselman, PH; Edgar, B; Kuntze, CE; Scaf, AH; Wesseling, H, 1989
)
0.88
" Differences in the distribution of blood flow before therapy combined with an interindividual variability in blood flow response during therapy is probably responsible for the observed impossibility to calculate trough levels, and thus oral dosage schedules, from intravenous pharmacokinetic data in patients with congestive heart failure."( Oral pharmacokinetics of felodipine in patients with congestive heart failure: variable prediction using intravenous data.
Dunselman, PH; Scaf, AH; Wesseling, H, 1989
)
0.58
" Systolic blood pressure and heart rate were recorded once a week just before dosing and at varying time intervals up to 6 hr thereafter."( Antihypertensive effect of spirapril and felodipine during repeated administration to spontaneously hypertensive rats.
Forlani, A; Milani, S; Monopoli, A; Ongini, E, 1988
)
0.54
" During long term treatment, blood pressure was significantly decreased after felodipine during the dosing interval (12h), irrespective of concomitant treatment."( Antihypertensive effects of felodipine compared with placebo.
Elmfeldt, D; Hedner, T, 1985
)
0.79
" Effects on blood pressure (BP) were evaluated after the first dose and after chronic dosing at 2 h after dosing and the end of the dosing interval (12 h)."( Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group.
, 1988
)
0.53
"0 h after dosing compared with placebo or indomethacin alone."( Effect of indomethacin on the pharmacokinetics and pharmacodynamics of felodipine.
Bailey, DG; Bartle, WR; Edgar, B; Hardy, BG; Myers, M, 1988
)
0.51
" Sixteen patients achieved the target DBP of 90 mmHg measured 12 hours after dosing and only one patient still had a DBP greater than 95 mmHg."( The effects of combining felodipine and metoprolol in moderate to severe hypertension--a one year study.
Chow, J, 1988
)
0.58
" Blood pressure was significantly reduced during the dosage interval of felodipine (12 h)."( Glucose tolerance in hypertensive patients during treatment with the calcium antagonist, felodipine.
Elmfeldt, D; Hedner, T; Sjögren, E; Smith, U; Von Schenck, H, 1987
)
0.73
" In the first study, 101 patients on a fixed combination of atenolol 100mg and chlorthalidone 25mg who required additional or 'third line' therapy for proper control, were randomised to either felodipine or hydralazine and the dosage was increased if the supine diastolic blood pressure was greater than 90mm Hg."( The use of felodipine in the treatment of severe hypertension.
Muir, AL; Wathen, CG, 1987
)
0.85
" After the increase in dosage blood pressure was lowered further."( Felodipine versus Moduretic. A double-blind parallel-group multicentre study.
Flygt, G; Krönig, B, 1987
)
1.72
" Plasma levels of digoxin and felodipine were measured before dosage and 30, 60 and 90 minutes and 2, 3, 4, 6, 8, 10 and 24 hours after the first dose and after 1 week of therapy (steady state)."( Pharmacokinetics of felodipine and effect on digoxin plasma levels in patients with heart failure.
Billing, E; Lundman, T; Moberg, L; Olsson, G; Rehnqvist, N, 1987
)
0.89
" The method was applied to urine collected from rats (n = 4, 0-24 h) after oral dosing of [14C] felodipine (5 mumol/kg)."( Bimodal column switching liquid chromatographic assay of six metabolites of [14C] felodipine in rat urine.
Weidolf, L, 1985
)
0.71
" Thus at the dosage used felodipine was a potent dilator of systemic arterioles but had no direct effect on left ventricular function."( Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease.
Culling, W; Ruttley, MS; Sheridan, DJ, 1984
)
0.86
" At the end of the dosing interval, felodipine lowered office DBP (mm Hg) by -18 +/- 12/14 +/- 1 compared to -14 +/- 2/11 +/- 1 for nifedipine (P < or = ."( Differential effects of felodipine and nifedipine on 24-h blood pressure and left ventricular mass.
Leenen, FH; Myers, MG; Tanner, J, 1995
)
0.87
" This finding highlights the need for new treatment strategies that are sufficiently effective throughout the dosing interval, well tolerated, and available in a convenient, once-daily regimen."( Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs--the rationale and benefits of combining felodipine and metoprolol.
Elmfeldt, D; Trenkwalder, P, 1995
)
0.49
" The exercise tests were performed at the end of dosage interval (i."( 24 h anti-anginal and anti-ischaemic effects with once daily felodipine. A double-blind comparison with nifedipine, twice daily, and placebo in patients with stable exercise induced angina pectoris.
Schulte, KL, 1995
)
0.53
"To characterize the population dose-response and concentration-response relationships of felodipine and to investigate the influence of patient variables on these relationships."( Felodipine population dose-response and concentration-response relationships in patients with essential hypertension.
Sambol, NC; Wade, JR, 1995
)
1.96
" The most common adverse events of the 54 and 28 cited as reasons for withdrawal in the felodipine and placebo groups respectively were increased need for non-study heart failure treatment (n = 10; 8%)--that is, starting new medication or changes in the dosage of existing treatment for patients given felodipine, and nausea (n = 4; 3%) for those given placebo."( Placebo controlled trial of felodipine in patients with mild to moderate heart failure. UK Study Group.
Littler, WA; Sheridan, DJ, 1995
)
0.81
" Further dosage adjustments are made in accordance with a set protocol."( The Hypertension Optimal Treatment (HOT) Study--patient characteristics: randomization, risk profiles, and early blood pressure results.
Hansson, L; Zanchetti, A, 1994
)
0.29
" Inclusion of cadmium (30 microM) in the physiological salt solution significantly reduced the maximum response, without significantly altering the ED50 or the Hill coefficient of the dose-response curve to methoxamine."( Role of intracellular and extracellular calcium in alpha 1-adrenoceptor-mediated vasoconstriction in the rat perfused hindquarters.
Tabrizchi, R,
)
0.13
" The variability in plasma concentrations over the dosing interval was found to be markedly less with the felodipine-metoprolol combination than with the combination of nifedipine and atenolol."( Aiming for steady 24-hour plasma concentrations: a comparison of two calcium antagonist and beta-blocker combinations.
Bergstrand, R; Eriksson, M; Lidman, K; Nyberg, G; Olofsson, B, 1993
)
0.5
" After a 3-week washout period, patients were randomized to receive felodipine-ER (5 mg once daily) or nifedipine GITS (30 mg once daily); during a subsequent 6-week titration phase, the once-daily felodipine-ER dose could be increased to 10 mg and the nifedipine GITS dose to 60 or 90 mg in an attempt to achieve adequate blood pressure response (SiDBP < or = 90 mm Hg, or < 100 mm Hg with a > 10-mm Hg reduction from baseline, as measured 24 hours after dosing [trough])."( Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension.
Fagan, TC; Haggert, BE; Liss, C,
)
0.63
" Correspondingly there was less variability with amlodipine in the blood pressure reductions across the dosage interval."( A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices.
Bainbridge, AD; Elliott, HL; Herlihy, O; Meredith, PA, 1993
)
0.55
" Blood pressure was measured 24 hours after dosing (at trough)."( Extended-release felodipine in patients with mild to moderate hypertension. Felodipine ER Dose-Response Study Group.
Faison, EP; Goldberg, AI; Irvin, JD; Lipschutz, K; Nelson, EB; Shapiro, DA; Weber, MA, 1994
)
0.63
"A new, once-daily combination tablet containing felodipine and metoprolol has been developed, using extended-release techniques to obtain even plasma concentrations throughout the dosing interval."( Design and pharmacokinetics of Logimax, a new extended-release combination tablet of felodipine and metoprolol.
Abrahamsson, B; Edgar, B; Lidman, K; Wingstrand, K, 1993
)
0.77
" After 12 weeks of active treatment, reductions in supine systolic/diastolic blood pressure 24 h after dosing were 20/14, 13/10 and 11/8 mmHg with felodipine-metoprolol, felodipine and metoprolol, respectively."( Antihypertensive efficacy and tolerability of a new once-daily felodipine-metoprolol combination compared with each component alone. The Swedish/UK Study Group.
Dahlöf, B; Hosie, J, 1993
)
0.73
" as basic antihypertensive treatment with the addition of a beta-blocker or an ACE-inhibitor in a second step, with further predetermined increments in dosage as required in order to obtain the randomized therapeutic goal."( The Hypertension Optimal Treatment Study (the HOT Study).
, 1993
)
0.29
" Four subjects withdrew during the randomised phases because of probable drug-related adverse events and six subjects required dosage reductions during the felodipine or combination phases."( Felodipine, metoprolol and their combination compared with placebo in isolated systolic hypertension in the elderly.
Bune, AJ; Chalmers, JP; Russell, AE; Tonkin, AL; West, MJ; Wing, LM, 1994
)
1.93
" Warfarin dosage was adjusted to achieve stable subtherapeutic anticoagulation."( Method for studying drug-warfarin interactions.
Aberg, J; Grind, M; Murphy, M; Warrington, S, 1993
)
0.29
" If seated DBP was > or = 90 mm Hg at any visit, daily dosage of felodipine was doubled to a maximum of 20 mg."( Antihypertensive effect and tolerability of felodipine extended release (ER) tablets in comparison with felodipine plain tablets (PT) and placebo in hypertensives on a diuretic. Canadian Study Group.
Carruthers, SG; Vint-Reed, C, 1993
)
0.79
" Blood samples for measurement of FEL and its pyridine metabolite (determined by gas-chromatography) were drawn just before dosing and at 2, 4, 6, 8, 10, 12, and 24 h after dosing on days 5, 6, and 13."( Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine.
Bendoni, L; Gangemi, PF; Menge, GP; Monza, GC; Schwabe, S; Zaccara, G, 1993
)
0.51
" In fertility, teratology and peri-postnatal studies Sprague-Dawley rats were dosed by gavage with 10, 25 and 70 mumol/kg (fertility and teratology studies) or 3, 10 and 30 mumol/kg (peri-postnatal study)."( Reproductive toxicity studies of the antihypertensive agent felodipine in the rat.
Danielson, MK; Danielsson, BR, 1993
)
0.53
" In patients with congestive heart failure, chronic dosing with felodipine produces a persistent reduction in vascular resistance and an increase in cardiac output, both at rest and during exercise."( Treatment of hypertension with felodipine in patients with concomitant diseases.
Gradman, AH, 1993
)
0.81
"The chemistry, pharmacology, pharmacokinetics, clinical uses, adverse effects, and dosage of felodipine and isradipine are reviewed."( Felodipine and isradipine: new calcium-channel-blocking agents for the treatment of hypertension.
Symes, LR; Walton, T, 1993
)
1.95
"5 mg) to fine-titrate the dosage to obtain optimal antihypertensive effects with minimal adverse effects."( Higher AUCs on oral administration of omeprazole and felodipine in Indian volunteers--are they clinically important?
Gowrishankar, R; Joseph, T, 1996
)
0.54
"5 mg is an appropriate starting dosage when initiating combination antihypertensive therapy."( Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy.
Bauer, B; Poisson, P; Rangoonwala, B; Schueler, E, 1996
)
0.66
" We have compared the pulmonary vasodilator effects, dose-response characteristics, and tolerability of two calcium channel blockers, amlodipine and extended-release (ER) felodipine, in 10 patients (seven men, age 68+/-4."( A comparison of two long-acting vasoselective calcium antagonists in pulmonary hypertension secondary to COPD.
Alpers, JA; Bune, AJ; Frith, PA; McEvoy, RD; Sajkov, D; Wang, T, 1997
)
0.49
" Their dose-response characteristics are similar, but amlodipine treatment was associated with fewer side effects."( A comparison of two long-acting vasoselective calcium antagonists in pulmonary hypertension secondary to COPD.
Alpers, JA; Bune, AJ; Frith, PA; McEvoy, RD; Sajkov, D; Wang, T, 1997
)
0.3
" Each patient was prescribed 5 mg of felodipine ER or 50 mg of atenolol once daily and this daily dosage was doubled to twice daily if necessary."( Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension.
Chern, MS; Lin, FC; Wu, D, 1997
)
0.8
"1% of the patients had responded to a total daily dosage of 5-10 mg of felodipine ER and 81."( Comparison of clinical efficacy and adverse effects between extended-release felodipine and atenolol in patients with mild and moderate essential hypertension.
Chern, MS; Lin, FC; Wu, D, 1997
)
0.76
" The coefficients of variation of maximal drug concentration and AUC after single dosing and at steady-state were significantly higher for felodipine ER than for amlodipine."( Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients.
Jacobsen, IA; Videbaek, LM, 1997
)
0.74
" The cardinal questions to be answered were: (1) the relationship between three targeted diastolic pressures (< or = 90, < or = 85 and < or = 80 mm Hg, respectively) and cardiovascular morbidity and mortality rates among hypertensives; and (2) the effect of low dosage aspirin (75 mg daily) on morbidity and mortality rates, compared with a placebo."( [The Hypertension Optimal Treatment (HOT) study: results of 12-month therapy related to age].
Kolloch, RE; Rahn, KH, 1998
)
0.3
" Any necessary changes in dosage (step 4) were made according to a prescribed plan."( [The Hypertension Optimal Treatment (HOT) study: results of 12-month therapy related to age].
Kolloch, RE; Rahn, KH, 1998
)
0.3
" After the first 4 weeks, the patients who responded to the initial dosage (a reduction in systolic blood pressure of at least 15 mm Hg) or whose blood pressure was controlled on the dosage (systolic blood pressure < 140 mm Hg) continued to take the low dose."( Felodipine extended release versus conventional diuretic therapy for the treatment of systolic hypertension in elderly patients. The National Trial Group.
McClennen, W; Wilson, T, 1998
)
1.74
" Amlodipine seems to be more effective than felodipine when the drugs are compared in the same dose, with regard to the effect on clinic BP 24 h after dosing and to ambulatory BP during the night."( Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension.
Brodin, U; Isaksson, H; Ohman, KP; Ostergren, J; Schwan, A, 1998
)
0.86
" Each patient received 50 mg of losartan or 5 mg of felodipine ER once daily, and the dosage was adjusted to double the initial level at week 6 if necessary."( Comparison of antihypertensive efficacy and tolerability of losartan and extended-release felodipine in patients with mild to moderate hypertension.
Cherng, WJ; Hsieh, IC; Hung, KC; Hung, MJ; Lin, FC; Wang, CH; Wen, MS; Wu, D, 1999
)
0.78
"The aim of the study was to identify the most appropriate dosage combination of ramipril and felodipine ER (an extended release tablet) for mild-to-moderate hypertension."( Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER.
Bauer, B; Massaro, J; Scholze, J, 1999
)
0.75
" Drug dosage was determined in an initial stepped-care titration phase lasting six weeks."( Reversal of left ventricular hypertrophy following once daily administration of felodipine for two years to elderly subjects with isolated systolic hypertension.
De Rosa, ML; Della Guardia, D; Giordano, A; Lionetti, F; Maddaluno, G; Marsicani, N; Vigorito, C, 1999
)
0.53
" In one study that titrated dosages to effect, fewer felodipine/metoprolol than felodipine or metoprolol monotherapy recipients required dosage increases to achieve BP control (45 vs 60 and 67%, respectively)."( Felodipine/metoprolol: a review of the fixed dose controlled release formulation in the management of essential hypertension.
Haria, M; Markham, A; Plosker, GL, 2000
)
2
" In addition, data were collected and analyzed with regard to adverse drug reactions, average dosage of the alternative calcium channel blocker, number of additional antihypertensives begun or discontinued, and number of dosage changes in antihypertensives within the two visits after conversion, and the overall cost impact of conversion."( Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers.
Beckey, NP; Korman, L; Parra, D, 2000
)
0.31
" Conversion to calcium channel antagonists other than felodipine or less than equal dosages of felodipine may require dosage titration."( Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers.
Beckey, NP; Korman, L; Parra, D, 2000
)
0.56
"The results suggest that once-daily dosing with either the free or fixed combination of felodipine 5 mg and metoprolol 50 mg produces a significant sustained reduction in systolic and diastolic BP with similar plasma concentration profiles over a 24-h period."( The pharmacodynamic and pharmacokinetic profiles of controlled-release formulations of felodipine and metoprolol in free and fixed combinations in elderly hypertensive patients.
Elliott, HL; Hosie, J; MacDonald, TM; McLay, JS, 2000
)
0.75
" Blood pressure was measured at the end of the dosing interval that is 24 hours and 12 hours after Felodipine and Nifedipine respectively."( A randomised trial to compare the efficacy and safety of Felodipine (Plendil) and Nifedipine (Adalat) retard in patients with mild-to-moderate hypertension.
Danbauchi, SS; Mbakwem, AC; Obodo, JO; Oke, DA; Okeahialam, BN; Onwubere, BJ,
)
0.59
" The dosage of ER felodipine was doubled to 10 mg/day and given for a further 2 weeks in non-responders (sitting clinic blood pressure > 140/90mm Hg)."( Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring.
Ansuini, R; Antonicelli, R; Gesuita, R; Giovanni, DC; Mori, A; Omboni, S; Paciaroni, E; Parati, G, 2002
)
0.89
" At variance with SI, T/P ratios did not increase in non-responders after doubling the dosage of ER felodipine (0."( Smooth blood pressure control obtained with extended-release felodipine in elderly patients with hypertension: evaluation by 24-hour ambulatory blood pressure monitoring.
Ansuini, R; Antonicelli, R; Gesuita, R; Giovanni, DC; Mori, A; Omboni, S; Paciaroni, E; Parati, G, 2002
)
0.77
" Doses were increased to 20 mg/day, 10 mg/day or 60 mg/day, respectively, if the office BP remained 160/90 mmHg or greater at the end of the dosing interval."( Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril.
Joyner, CD; Leenen, FH; Myers, MG; Toal, CB, 2002
)
0.51
"On 24 h ambulatory BP monitoring, nifedipine-GITS caused a consistent decrease in BP throughout the 24 h dosing interval, whereas felodipine-ER caused a more marked fall in BP during the day, and enalapril's effects diminished during the night and had disappeared by the morning."( Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: Nifedipine-GITS versus felodipine-ER versus enalapril.
Joyner, CD; Leenen, FH; Myers, MG; Toal, CB, 2002
)
0.72
" There is a need for efficacious, safe, and well-tolerated antihypertensive agents with a once-a-day dosing regimen in children and adolescents."( Clinical trial of extended-release felodipine in pediatric essential hypertension.
Frank, R; Klibaner, M; Mahan, JD; Matoo, TK; Portman, R; Restaino, I; Tou, C; Trachtman, H, 2003
)
0.6
" The percentage of patients who required a warfarin dosage adjustment based on the post-INR (secondary outcome measure) was 41% (9 of 22 patients) in the levofloxacin group and 33% (7 of 21 patients) in the felodipine group."( Retrospective evaluation of a possible interaction between warfarin and levofloxacin.
Anderson, HG; McCall, KL; Scott, JC, 2005
)
0.52
" The SAS process system may be used to enhance solubility or to produce oral dosage forms with high dissolution rate."( Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process.
Hwang, SJ; Kim, MS; Lee, S; Park, JS; Won, DH, 2005
)
0.59
" The ramipril/felodipine ER combination is as well tolerated as ramipril or felodipine ER monotherapy administered at the same dosages, and is better tolerated than felodipine ER monotherapy given at twice the dosage used in the combination."( Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.
Cvetković, RS; Plosker, GL, 2005
)
1.11
"Gastrointestinal motility and transport as well as concomitant food intake are factors that are known to influence pharmacokinetics derived after intake of extended release dosage forms."( Impact of the intragastric location of extended release tablets on food interactions.
Abrahamsson, B; Fach, K; Kosch, O; Mönnikes, H; Nagel, S; Söderlind, E; Trahms, L; Wedemeyer, RS; Weitschies, W, 2005
)
0.33
"Crystallization of drugs formulated in the amorphous form may lead to reduced apparent solubility, decreased rate of dissolution and bioavailability and compromise the physical integrity of the solid dosage form."( Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility.
Marsac, PJ; Shamblin, SL; Taylor, LS, 2006
)
0.33
" CCAs can be safely used in children with renal insufficiency or failure and as a general rule there is no need to modify drug dosage in this population."( A review of calcium channel antagonists in the treatment of pediatric hypertension.
Sahney, S, 2006
)
0.33
" The FDA has recently issued an alert regarding the potential negative influence of alcohol on extended release dosage forms."( The influence of hydro-alcoholic media on hypromellose matrix systems.
Levina, M; Rajabi-Siahboomi, AR; Vuong, H, 2007
)
0.34
"260 patients with mild to moderate primary hypertension, aged 35-79, received slow releasing felodipine with the initial dosage of 5 mg once daily for 2 weeks."( [Curative effects on mild to moderate primary hypertension and influence on pulse wave velocity of slow releasing felodipine].
Jing, S; Sun, NL, 2008
)
0.78
" Therefore the present study's objective was to provide clarification of previous findings, adopting a two-way approach, involving both single dose and multiple dosage regimens."( Influence of grapefruit juice on the pharmacokinetics of diltiazem in Wistar rats upon single and multiple dosage regimens.
Avery, BA; Boddu, SP; Kuma, SV; Potharaju, S; Rajak, S; Repka, MA; Varanasi, VS; Veeraraghavan, S; Yamsani, MR, 2009
)
0.35
" The morning dosage was titrated if the goal blood pressure was not achieved."( [Impact of antihypertensive medication timing on degree and stability of blood pressure lowering in patients with essential hypertension].
Bai, B; Cui, TQ; Hou, JN; Jiang, LS; Mu, CL; Zhao, CP, 2009
)
0.35
" In the young subjects, the first dose of either DHP did not decrease BP and chronic dosing decreased BP by approximately 10 mm Hg, which had disappeared by 24 hours."( Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension.
Coletta, E; Leenen, FH, 2010
)
0.6
"The purpose of the present research was to develop bioadhesive buccal tablets for Felodipine (FDP) and Pioglitazone (PIO), low bioavailability drugs, in a combined dosage form for the management of diabetes and hypertension."( Development of bioadhesive buccal tablets for felodipine and pioglitazone in combined dosage form: in vitro, ex vivo, and in vivo characterization.
Gannu, R; Palem, CR; Yamsani, MR; Yamsani, SK; Yamsani, VV, 2011
)
0.85
" As inkjet printing is an inherently scalable technology, this proof of principal work with single deposited micro-spot formulations demonstrates the potential of this approach to print practical dosage forms (e."( Inkjet printing as a novel medicine formulation technique.
Alexander, MR; Gellert, PR; Roberts, CJ; Scoutaris, N, 2011
)
0.37
"Tomographic imaging techniques are attractive tools for the visualization of the internal structural characteristics of pharmaceutical solid dosage forms."( Microstructural investigation to the controlled release kinetics of monolith osmotic pump tablets via synchrotron radiation X-ray microtomography.
He, Y; Ji, J; Li, H; Shao, Q; Sun, L; Xiao, T; Yin, X; York, P; Zhang, J, 2012
)
0.38
" Blood samples were withdrawn from retro-orbital plexus on first day in single dose PK study (SDS) and on 15th day in multiple dosing PK study (MDS)."( Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro.
Naveen Babu, K; Puneeth, Y; Ravindra Babu, P; Sridhar, V; Surya Sandeep, M, 2014
)
0.68
" It is of paramount significance from the perspective of pharmaceutical analysis and dosage form design."( Determination of pK(a) of felodipine using UV-Visible spectroscopy.
Charde, SY; Jaipal, A; Kumar, A; Malik, R; Pandey, MM, 2013
)
0.69
" We have recently found that supersaturating dosage forms can exhibit the phenomenon of liquid-liquid phase separation (LLPS)."( Enhancements and limits in drug membrane transport using supersaturated solutions of poorly water soluble drugs.
Alonzo, DE; Catron, ND; Gao, Y; Raina, SA; Taylor, LS; Wu, J; Zhang, GGZ; Zhu, D, 2014
)
0.4
"We have employed for the first time Raman spectroscopic imaging along with multi-variate curve resolution (MCR) analysis to investigate in real time and in-situ the dissolution mechanisms that underpin amorphous solid dispersions, with data being collected directly from the dosage form itself."( Real time Raman imaging to understand dissolution performance of amorphous solid dispersions.
Aylott, JW; Booth, J; Burley, JC; Hughes, LP; Treacher, K; Tres, F; Wren, SA, 2014
)
0.4
" The method has been validated according to International Conference on Harmonization guidelines and has been successfully applied for determination of the studied drugs in their dosage forms without interference from commonly encountered excipients."( Development and validation of TLC-densitometric method for simultaneous determination of two binary antihypertensive mixtures containing felodipine in fixed dose combinations.
Hammad, MA; Mohamed, AA; Mohamed, AM; Omar, MA, 2016
)
0.64
"The bioavailability of orally administered drugs that exhibit poor aqueous solubility can be enhanced with the use of supersaturating dosage forms."( Influence of Polymers on the Crystal Growth Rate of Felodipine: Correlating Adsorbed Polymer Surface Coverage to Solution Crystal Growth Inhibition.
Beaudoin, SP; Schram, CJ; Taylor, LS, 2015
)
0.67
"Creating in situ phase separation in solid dispersion based formulations to allow enhanced functionality of the dosage form, such as improving dissolution of poorly soluble model drug as well as being mucoadhesive, can significantly maximize the in vitro and in vivo performance of the dosage form."( Creating Drug Solubilization Compartments via Phase Separation in Multicomponent Buccal Patches Prepared by Direct Hot Melt Extrusion-Injection Molding.
Alhijjaj, M; Belton, P; Bouman, J; Qi, S; Wellner, N, 2015
)
0.42
" These results can be a good opportunity to design new photoprotective pharmaceutical packaging for DHPs in liquid dosage form."( Photostabilization studies of antihypertensive 1,4-dihydropyridines using polymeric containers.
De Luca, M; Ioele, G; Ragno, G; Spatari, C, 2016
)
0.43
" However, commercially available FDM printers are extremely limited with regards to the materials that can be processed to few types of thermoplastic polymers, which often may not be pharmaceutically approved materials nor ideal for optimizing dosage form performance of poor soluble compounds."( An investigation into the use of polymer blends to improve the printability of and regulate drug release from pharmaceutical solid dispersions prepared via fused deposition modeling (FDM) 3D printing.
Alhijjaj, M; Belton, P; Qi, S, 2016
)
0.43
" With regards to in vitro dissolution assessment of these dosage forms, human saliva should be represented by the dissolution media."( Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine.
Ali, J; Burley, JC; Garnett, MC; Gershkovich, P; Hameed, GS; Roberts, CJ; Zgair, A, 2019
)
0.73
"This study uses high drug content solid dispersions for dose window extension beyond current demonstrations using fused deposition modelling (FDM) to; i) accommodate pharmaceutically relevant doses of drugs of varying potencies at acceptable dosage form sizes and ii) enable enhanced dose flexibility via modular dosage form design concepts."( High Content Solid Dispersions for Dose Window Extension: A Basis for Design Flexibility in Fused Deposition Modelling.
Abrahmsén-Alami, S; Folestad, S; Govender, R; Larsson, A, 2019
)
0.51
" The achieved uniformity of content supports the application of varying content solid dispersions to modular dosage form concepts to enhance dose flexibility."( High Content Solid Dispersions for Dose Window Extension: A Basis for Design Flexibility in Fused Deposition Modelling.
Abrahmsén-Alami, S; Folestad, S; Govender, R; Larsson, A, 2019
)
0.51
" These findings may apply to drugs administered as a single dosage form or in separate dosage forms and hence need to be well controlled to assure effective treatments and patient safety."( Insights into Dissolution and Solution Chemistry of Multidrug Formulations of Antihypertensive Drugs.
Alhalaweh, A; Bergström, CAS; El Sayed, M, 2020
)
0.56
"Multidrug dosage forms (aka combination dosage forms, polypills, etc."( Enabling modular dosage form concepts for individualized multidrug therapy: Expanding the design window for poorly water-soluble drugs.
Abrahmsén-Alami, S; Folestad, S; Govender, R; Larsson, A; Olsson, M, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
calcium channel blockerOne of a class of drugs that acts by selective inhibition of calcium influx through cell membranes or on the release and binding of calcium in intracellular pools.
antihypertensive agentAny drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism.
vasodilator agentA drug used to cause dilation of the blood vessels.
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
dihydropyridine
dichlorobenzeneAny member of the class of chlorobenzenes carrying two chloro groups at unspecified positions.
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Felodipine Action Pathway478
Felodipine Metabolism Pathway31

Protein Targets (76)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency33.55210.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency40.07495.623417.292931.6228AID2323; AID485281
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
LuciferasePhotinus pyralis (common eastern firefly)Potency37.93300.007215.758889.3584AID588342
acid sphingomyelinaseHomo sapiens (human)Potency25.118914.125424.061339.8107AID504937
endonuclease IVEscherichia coliPotency19.95260.707912.432431.6228AID1708
glp-1 receptor, partialHomo sapiens (human)Potency10.12580.01846.806014.1254AID624172; AID624417; AID743262
RAR-related orphan receptor gammaMus musculus (house mouse)Potency13.33320.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency25.91850.004110.890331.5287AID493107
Fumarate hydrataseHomo sapiens (human)Potency31.62280.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency45.85770.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency24.14940.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency12.47930.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency14.41510.000221.22318,912.5098AID1259243; AID1259247; AID743036; AID743053
Smad3Homo sapiens (human)Potency28.93420.00527.809829.0929AID588855
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency14.96010.000657.913322,387.1992AID1259378
progesterone receptorHomo sapiens (human)Potency3.75780.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency4.36490.01237.983543.2770AID1645841
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency56.23410.28189.721235.4813AID2326
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency10.68220.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency23.36670.003041.611522,387.1992AID1159552; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency18.66280.001530.607315,848.9004AID1224819; AID1224820; AID1224821; AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency28.22410.375827.485161.6524AID743220; AID743239
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.40150.000229.305416,493.5996AID743069; AID743075
GVesicular stomatitis virusPotency2.18760.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency24.54540.00108.379861.1304AID1645840
polyproteinZika virusPotency31.62280.00308.794948.0869AID1347053
ParkinHomo sapiens (human)Potency2.59290.819914.830644.6684AID720572
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency19.24170.001024.504861.6448AID743212; AID743227
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency15.84890.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency1.88340.000723.06741,258.9301AID743085
activating transcription factor 6Homo sapiens (human)Potency23.91450.143427.612159.8106AID1159516
Bloom syndrome protein isoform 1Homo sapiens (human)Potency25.11890.540617.639296.1227AID2364; AID2528
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency35.48130.036619.637650.1187AID2100
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency23.934123.934123.934123.9341AID1967
chromobox protein homolog 1Homo sapiens (human)Potency45.85770.006026.168889.1251AID488953; AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency19.95260.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency18.13790.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency26.60110.042027.378961.6448AID743210
flap endonuclease 1Homo sapiens (human)Potency8.43680.133725.412989.1251AID588795
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency20.74910.00378.618923.2809AID2668
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency21.27020.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency15.08490.004611.374133.4983AID463097; AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency37.68580.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency18.10560.005612.367736.1254AID624032
M-phase phosphoprotein 8Homo sapiens (human)Potency36.53380.177824.735279.4328AID488949
lamin isoform A-delta10Homo sapiens (human)Potency30.30510.891312.067628.1838AID1459; AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency11.29470.015812.3113615.5000AID1461
Interferon betaHomo sapiens (human)Potency12.87890.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency2.18760.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency29.84930.002319.595674.0614AID651631
Alpha-synucleinHomo sapiens (human)Potency29.09290.56239.398525.1189AID652106
Guanine nucleotide-binding protein GHomo sapiens (human)Potency28.18381.995325.532750.1187AID624288
TAR DNA-binding protein 43Homo sapiens (human)Potency35.48131.778316.208135.4813AID652104
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency44.66843.981146.7448112.2020AID720708
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency2.18760.01238.964839.8107AID1645842
Ataxin-2Homo sapiens (human)Potency28.18380.011912.222168.7989AID588378
cytochrome P450 2C9, partialHomo sapiens (human)Potency2.18760.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cathepsin BHomo sapiens (human)IC50 (µMol)50.00000.001514.100845.9741AID820
procathepsin L isoform 1 preproproteinHomo sapiens (human)IC50 (µMol)50.00000.00163.961431.1549AID1627
fructose-bisphosphate aldolaseMycobacterium tuberculosis H37RvIC50 (µMol)9.99100.37031.78605.8150AID652135
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)69.70000.11007.190310.0000AID1473738
ATP-dependent translocase ABCB1Homo sapiens (human)IC50 (µMol)39.53330.00022.318510.0000AID681126; AID681127; AID681131
Adenosine receptor A3Homo sapiens (human)IC50 (µMol)1.05700.00001.89408.5470AID625196
Adenosine receptor A3Homo sapiens (human)Ki0.59700.00000.930610.0000AID625196
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)4.57950.00002.800510.0000AID625248
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)1.05700.00021.874210.0000AID625196
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki0.59700.00010.949010.0000AID625196
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)1.05700.00001.819410.0000AID625196
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki0.59700.00000.965010.0000AID625196
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Bile acid receptorHomo sapiens (human)IC50 (µMol)4.96000.01834.560310.0000AID755454
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nuclear receptor subfamily 1 group I member 2Homo sapiens (human)EC50 (µMol)4.30000.00203.519610.0000AID1215086; AID1215087; AID1215094
Aurora kinase BHomo sapiens (human)Kd1.14000.00201.061422.8520AID1801811
Nuclear receptor subfamily 1 group I member 2Rattus norvegicus (Norway rat)EC50 (µMol)23.40000.01004.139410.0000AID1215090
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (413)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
negative regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
signal transductionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
steroid metabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of gene expressionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic catabolic processNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
xenobiotic transportNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
cell differentiationNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 1 group I member 2Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
inflammatory responseAdenosine receptor A3Homo sapiens (human)
signal transductionAdenosine receptor A3Homo sapiens (human)
activation of adenylate cyclase activityAdenosine receptor A3Homo sapiens (human)
regulation of heart contractionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A3Homo sapiens (human)
response to woundingAdenosine receptor A3Homo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A3Homo sapiens (human)
negative regulation of cell migrationAdenosine receptor A3Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activityAdenosine receptor A3Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A3Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A3Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAurora kinase BHomo sapiens (human)
mitotic cell cycleAurora kinase BHomo sapiens (human)
mitotic cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of B cell apoptotic processAurora kinase BHomo sapiens (human)
protein phosphorylationAurora kinase BHomo sapiens (human)
spindle organizationAurora kinase BHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
abscissionAurora kinase BHomo sapiens (human)
negative regulation of protein bindingAurora kinase BHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseAurora kinase BHomo sapiens (human)
negative regulation of cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of cytokinesisAurora kinase BHomo sapiens (human)
protein localization to kinetochoreAurora kinase BHomo sapiens (human)
cellular response to UVAurora kinase BHomo sapiens (human)
cleavage furrow formationAurora kinase BHomo sapiens (human)
post-translational protein modificationAurora kinase BHomo sapiens (human)
cell cycle G2/M phase transitionAurora kinase BHomo sapiens (human)
mitotic cytokinesis checkpoint signalingAurora kinase BHomo sapiens (human)
negative regulation of innate immune responseAurora kinase BHomo sapiens (human)
protein autophosphorylationAurora kinase BHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase BHomo sapiens (human)
positive regulation of telomerase activityAurora kinase BHomo sapiens (human)
regulation of chromosome segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointAurora kinase BHomo sapiens (human)
mitotic spindle assemblyAurora kinase BHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayAurora kinase BHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid separationAurora kinase BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
positive regulation of mitotic cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of telomere cappingAurora kinase BHomo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
mitotic spindle organizationAurora kinase BHomo sapiens (human)
regulation of cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of very-low-density lipoprotein particle remodelingBile acid receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionBile acid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
nitrogen catabolite activation of transcription from RNA polymerase II promoterBile acid receptorHomo sapiens (human)
intracellular glucose homeostasisBile acid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
inflammatory responseBile acid receptorHomo sapiens (human)
cell-cell junction assemblyBile acid receptorHomo sapiens (human)
Notch signaling pathwayBile acid receptorHomo sapiens (human)
bile acid metabolic processBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor-mediated signaling pathwayBile acid receptorHomo sapiens (human)
regulation of low-density lipoprotein particle clearanceBile acid receptorHomo sapiens (human)
intracellular receptor signaling pathwayBile acid receptorHomo sapiens (human)
negative regulation of type II interferon productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-1 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-2 productionBile acid receptorHomo sapiens (human)
negative regulation of interleukin-6 productionBile acid receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionBile acid receptorHomo sapiens (human)
positive regulation of interleukin-17 productionBile acid receptorHomo sapiens (human)
toll-like receptor 9 signaling pathwayBile acid receptorHomo sapiens (human)
regulation of urea metabolic processBile acid receptorHomo sapiens (human)
intracellular triglyceride homeostasisBile acid receptorHomo sapiens (human)
positive regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
bile acid signaling pathwayBile acid receptorHomo sapiens (human)
intracellular bile acid receptor signaling pathwayBile acid receptorHomo sapiens (human)
cholesterol homeostasisBile acid receptorHomo sapiens (human)
defense response to bacteriumBile acid receptorHomo sapiens (human)
negative regulation of apoptotic processBile acid receptorHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionBile acid receptorHomo sapiens (human)
innate immune responseBile acid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIBile acid receptorHomo sapiens (human)
positive regulation of insulin receptor signaling pathwayBile acid receptorHomo sapiens (human)
fatty acid homeostasisBile acid receptorHomo sapiens (human)
regulation of insulin secretion involved in cellular response to glucose stimulusBile acid receptorHomo sapiens (human)
regulation of bile acid biosynthetic processBile acid receptorHomo sapiens (human)
cellular response to lipopolysaccharideBile acid receptorHomo sapiens (human)
cellular response to fatty acidBile acid receptorHomo sapiens (human)
cellular response to organonitrogen compoundBile acid receptorHomo sapiens (human)
negative regulation of monocyte chemotactic protein-1 productionBile acid receptorHomo sapiens (human)
regulation of cholesterol metabolic processBile acid receptorHomo sapiens (human)
cellular response to bile acidBile acid receptorHomo sapiens (human)
positive regulation of adipose tissue developmentBile acid receptorHomo sapiens (human)
positive regulation of phosphatidic acid biosynthetic processBile acid receptorHomo sapiens (human)
positive regulation of glutamate metabolic processBile acid receptorHomo sapiens (human)
positive regulation of ammonia assimilation cycleBile acid receptorHomo sapiens (human)
cell differentiationBile acid receptorHomo sapiens (human)
negative regulation of inflammatory responseBile acid receptorHomo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (139)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear receptor bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A3Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase BHomo sapiens (human)
protein bindingAurora kinase BHomo sapiens (human)
ATP bindingAurora kinase BHomo sapiens (human)
kinase bindingAurora kinase BHomo sapiens (human)
protein serine kinase activityAurora kinase BHomo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
transcription coregulator bindingBile acid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificBile acid receptorHomo sapiens (human)
DNA-binding transcription factor activityBile acid receptorHomo sapiens (human)
nuclear receptor activityBile acid receptorHomo sapiens (human)
protein bindingBile acid receptorHomo sapiens (human)
zinc ion bindingBile acid receptorHomo sapiens (human)
nuclear receptor bindingBile acid receptorHomo sapiens (human)
bile acid bindingBile acid receptorHomo sapiens (human)
bile acid receptor activityBile acid receptorHomo sapiens (human)
sequence-specific DNA bindingBile acid receptorHomo sapiens (human)
nuclear retinoid X receptor bindingBile acid receptorHomo sapiens (human)
chenodeoxycholic acid bindingBile acid receptorHomo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (88)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nuclear bodyNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
intermediate filament cytoskeletonNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 1 group I member 2Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
presynaptic membraneAdenosine receptor A3Homo sapiens (human)
Schaffer collateral - CA1 synapseAdenosine receptor A3Homo sapiens (human)
dendriteAdenosine receptor A3Homo sapiens (human)
plasma membraneAdenosine receptor A3Homo sapiens (human)
synapseAdenosine receptor A3Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
condensed chromosome, centromeric regionAurora kinase BHomo sapiens (human)
nucleusAurora kinase BHomo sapiens (human)
nucleoplasmAurora kinase BHomo sapiens (human)
spindleAurora kinase BHomo sapiens (human)
cytosolAurora kinase BHomo sapiens (human)
chromocenterAurora kinase BHomo sapiens (human)
microtubule cytoskeletonAurora kinase BHomo sapiens (human)
midbodyAurora kinase BHomo sapiens (human)
chromosome passenger complexAurora kinase BHomo sapiens (human)
mitotic spindle poleAurora kinase BHomo sapiens (human)
mitotic spindle midzoneAurora kinase BHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
spindle pole centrosomeAurora kinase BHomo sapiens (human)
spindle microtubuleAurora kinase BHomo sapiens (human)
spindle midzoneAurora kinase BHomo sapiens (human)
nucleoplasmBile acid receptorHomo sapiens (human)
chromatinBile acid receptorHomo sapiens (human)
euchromatinBile acid receptorHomo sapiens (human)
receptor complexBile acid receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexBile acid receptorHomo sapiens (human)
nucleusBile acid receptorHomo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (256)

Assay IDTitleYearJournalArticle
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID23635Plasma half-life in dogs after intravenous administration1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists.
AID540229Volume of distribution at steady state in human after iv administration2006Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID122567Anticonvulsant activity in the maximal electroshock (MES) screen test expressed as the number of animals protected / the number of animals tested; MES at 300 mg/kg after 0.5 hrs; (1/1)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID19136Compound was evaluated for the plasma half-life to investigate its pharmacokinetic profile in dogs after intravenous administration. 1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine.
AID122566Anticonvulsant activity in the maximal electroshock (MES) screen test expressed as the number of animals protected / the number of animals tested; MES at 100 mg/kg after 4 hrs; (2/3)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1223490Apparent permeability across human differentiated Caco2 cells2012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID1473770AUC in human at 2.5 to 10 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1215094Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID227699Virtual screen for compounds with anticonvulsant activity2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID1215099Selectivity ratio of EC50 for rat PXR to EC50 for human PAR2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID29362Dissociation constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID540228Clearance in human after iv administration2006Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID755454Antagonist activity at human GTS-tagged FXR after 20 mins by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID243422log (1/Km) value for human liver microsome cytochrome P450 3A42005Bioorganic & medicinal chemistry letters, Sep-15, Volume: 15, Issue:18
Modeling K(m) values using electrotopological state: substrates for cytochrome P450 3A4-mediated metabolism.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID122708Anticonvulsant activity in the subcutaneous metrazole (scMet) screen test expressed as the number of animals protected/ the number of animals tested; scMet at 300 mg/kg after 0.5 hrs; (0/1)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID681126TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID29423HPLC capacity factor (k')2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID21288Compound was evaluated for the plasma clearance to investigate its pharmacokinetic profile in dogs after intravenous administration. 1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine.
AID21438Compound was tested for the plasma clearance in dogs1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID1473771Drug concentration at steady state in human at 2.5 to 10 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID22992Compound was tested for the volume of distribution in dogs1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID21852In vitro clearance in rat in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID540227Volume of distribution at steady state in monkey after iv administration2006Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID29344Ionisation constant (pKa)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID681131TP_TRANSPORTER: inhibition of Daunorubicin efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID117805Anticonvulsant activity in the subcutaneous metrazole (scMet) screen test expressed as the number of animals protected / the number of animals tested; scMet at 300 mg/kg after 4 hrs1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID28677Partition coefficient (logD)2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID122565Anticonvulsant activity in the maximal electroshock (MES) screen test expressed as the number of animals protected / the number of animals tested; MES at 100 mg/kg after 0.5 hrs; (2/3)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID717844Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID444050Fraction unbound in human plasma2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1215089Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID28235Unbound fraction (plasma)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID302758Solubility by shake flask method2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
Poorly soluble marketed drugs display solvation limited solubility.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID30135Volume of distribution of the compound2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID21434Plasma clearance in dogs after intravenous administration1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID755445Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation after 16 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID1061889Displacement of [3H]BTX-B from neuronal voltage-gated sodium channel in rat cerebral cortex synaptoneurosomes after 60 mins by scintillation counting2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
A highly predictive 3D-QSAR model for binding to the voltage-gated sodium channel: design of potent new ligands.
AID122699Anticonvulsant activity in the subcutaneous metrazole (scMet) screen test expressed as the number of animals protected / the number of animals tested; scMet at 100 mg/kg after 4 hrs; (0/1)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID540224Clearance in dog after iv administration2006Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID681127TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells2001Biochemical and biophysical research communications, Nov-30, Volume: 289, Issue:2
Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors.
AID1215096Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to rifampicin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID515314Octanol-water partition coefficient, log P of the compound2010European journal of medicinal chemistry, Oct, Volume: 45, Issue:10
Antihypertensive and antiarrhythmic properties of a para-hydroxy[bis(ortho-morpholinylmethyl)]phenyl-1,4-DHP compound: comparison with other compounds of the same kind and relationship with logP values.
AID1215095Competitive binding affinity to human PXR LBD (111 to 434) by TR-FRET assay relative to SR128132011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID21851In vitro clearance in human in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID28233Fraction ionized (pH 7.4)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1215086Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID21474Compound was tested for the plasma half life in dogs1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic substituents.
AID27900Plasma clearance of the compound2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID540223Volume of distribution at steady state in rat after iv administration2006Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID592681Apparent permeability across human Caco2 cell membrane after 2 hrs by LC-MS/MS analysis2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
QSAR-based permeability model for drug-like compounds.
AID540225Volume of distribution at steady state in dog after iv administration2006Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID453618Inhibition of L-VDCC in rat H9C2 cells assessed as effect on calcium level by Fluo-4 fluorescence assay2009Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23
Synthesis of 4-thiophen-2'-yl-1,4-dihydropyridines as potentiators of the CFTR chloride channel.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID640615Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.
AID1473772Ratio of drug concentration at steady state in human at 2.5 to 10 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID21859In vivo clearance in rat.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1215090Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1215097Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis relative to dexamethasone2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID29925Volume of distribution in man (IV dose)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID755455Antagonist activity at human GTS-tagged FXR at 15 uM after 20 mins by TR-FRET assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID540222Clearance in rat after iv administration2006Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID117801Anticonvulsant activity in the maximal electroshock (MES) screen test expressed as the number of animals protected / the number of animals tested; MES at 300 mg/kg after 4 hr; not determined1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1215087Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Identification of clinically used drugs that activate pregnane X receptors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID26380Dissociation constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID755449Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation at 40 uM after 16 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Jul-15, Volume: 21, Issue:14
Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID21857In vivo clearance in human.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID602033Solubility of compound in HBSS buffer of pH 6.5 by LC-UV/MS2011Bioorganic & medicinal chemistry letters, May-15, Volume: 21, Issue:10
A novel series of piperazinyl-pyridine ureas as antagonists of the purinergic P2Y12 receptor.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID122698Anticonvulsant activity in the subcutaneous metrazole (scMet) screen test expressed as the number of animals protected / the number of animals tested; scMet at 100 mg/kg after 0.5 hrs; (0/1)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID21849In vitro clearance in dog in 1000000 cells1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID29851Half life was measured as time taken to decrease half of its initial concentration2001Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9
Property-based design: optimization of drug absorption and pharmacokinetics.
AID21854In vivo clearance in dog.1999Journal of medicinal chemistry, Dec-16, Volume: 42, Issue:25
Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques.
AID12234881-Octanol-water distribution coefficient, log D of the compound at pH 7.42012Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2
Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID22990Compound was evaluated for the volume of distribution to investigate its pharmacokinetic profile in dogs after intravenous administration. 1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Long-acting dihydropyridine calcium antagonists. 6. Structure-activity relationships around 4-(2,3-dichlorophenyl)-3-(ethoxycarbonyl)-2-[(2-hydroxyethoxy)methyl]-5 -(methoxycarbonyl)-6-methyl-1,4-dihydropyridine.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID681353TP_TRANSPORTER: increase in Vinblastine intracellular accumulation in F4-6RADR cells1992Biochemical pharmacology, Jun-23, Volume: 43, Issue:12
Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein.
AID22995Volume of distribution in dogs after intravenous administration1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2-[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists.
AID540226Clearance in monkey after iv administration2006Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 34, Issue:7
Extrapolation of preclinical pharmacokinetics and molecular feature analysis of "discovery-like" molecules to predict human pharmacokinetics.
AID28236Unbound fraction (tissues)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID18735Partition coefficient; Kp = concentration of test compound in n-octanol/concentration of the test compound in phosphate buffer (pH 7.4)1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID78018Calcium channel antagonist activity against carbachol-induced contractile response in guinea pig ileal longitudinal smooth muscle1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1346885Human CFTR (CFTR)2007Molecular pharmacology, Jul, Volume: 72, Issue:1
Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID493017Wombat Data for BeliefDocking1996Journal of medicinal chemistry, Nov-08, Volume: 39, Issue:23
Synthesis, biological evaluation, calcium channel antagonist activity, and anticonvulsant activity of felodipine coupled to a dihydropyridine-pyridinium salt redox chemical delivery system.
AID1801811Isothermal Titration Calorimetry (ITC) from Article 10.1111/cbdd.12728: \\A Dual Non-ATP Analogue Inhibitor of Aurora Kinases A and B, Derived from Resorcinol with a Mixed Mode of Inhibition.\\2016Chemical biology & drug design, 06, Volume: 87, Issue:6
A Dual Non-ATP Analogue Inhibitor of Aurora Kinases A and B, Derived from Resorcinol with a Mixed Mode of Inhibition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,266)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990275 (21.72)18.7374
1990's523 (41.31)18.2507
2000's200 (15.80)29.6817
2010's216 (17.06)24.3611
2020's52 (4.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 81.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index81.32 (24.57)
Research Supply Index7.47 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index147.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (81.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials421 (31.70%)5.53%
Reviews60 (4.52%)6.00%
Case Studies35 (2.64%)4.05%
Observational0 (0.00%)0.25%
Other812 (61.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (21)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Open Label, Randomized, Comparative Study of Ramipril 5mg Plus Felodipine 5mg Combined Regimen and Ramipril 10mg in Uncontrolled Hypertensive Patients [NCT00841880]Phase 449 participants (Actual)Interventional2009-01-31Completed
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Felodipine Extended Release Tablet (Containing Felodipine 10 mg) of OHM Laboratories Inc (A Subsidiary of Ranbaxy Pharmace [NCT02311530]80 participants (Actual)Interventional2008-10-31Completed
Felodipine Event Reduction Study [NCT01136863]9,800 participants (Actual)Interventional1998-04-30Completed
Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension [NCT01238705]Phase 4280 participants (Anticipated)Interventional2008-04-30Recruiting
Blood Pressure and Weight Trajectory on a Dual Antihypertensive Combination Plus Sibutramine Versus Placebo in Obese Hypertensives [NCT00679653]Phase 3171 participants (Actual)Interventional2002-02-28Completed
Felodipine Controlled Release Tablets and Felodipine Sustained Release Tablets in Healthy Subjects Under Fasting State: Single Dose, Randomized, Open, 2-treatment,2-period,Crossover Comparative Pharmacokinetic Study [NCT05614037]Phase 116 participants (Actual)Interventional2022-10-28Active, not recruiting
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine in a Combination Package Compared to the Separate Intake of the Reference Brands Atacand and Splendil After a Fasting Period. [NCT00905333]Phase 136 participants (Actual)Interventional2008-10-31Completed
Insulin-induced Microvascular Activity in Patients With Essential Hypertension: a Possible Role for Angiotensin II AT1-receptor Blockers. [NCT00742066]32 participants (Anticipated)Interventional2008-03-31Active, not recruiting
An Open-Label, Non-Comparative, Multi-Centre Study to Evaluate the Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet (Betaloc Zok) in Patients With Mild to Moderate Essential Hypertension [NCT00861016]Phase 4310 participants (Actual)Interventional2005-10-31Completed
Prospektivt Randomiseret Dobbeltblindt Placebo-kontrolleret Studie af, Calciumkanalblokade påbegyndt Inden Operation: Med Henblik på at Forebygge Ciclosporin Induceret Nefropati Efter Lungetransplantation [NCT02744872]Phase 442 participants (Actual)Interventional2013-09-30Completed
A Multicenter, Non-comparative, Phase IV Study to Evaluate the Effect of Candesartan Based Therapy in the Percent Change of proBNP Level After 24 Week Treatment in the Patients With Hypertension With Left Ventricular Hypertrophy [NCT00348686]Phase 4315 participants (Actual)Interventional2006-06-30Completed
Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina [NCT00507845]Phase 4271 participants (Actual)Interventional2007-06-30Completed
An Open Label, Randomised, 2-period, 2-treatment, 2-sequence, Cross-over, Single-dose Bioequivalence Study of Felodipine Extended-Release Tablets USP 10 mg (Test, Torrent Pharmaceuticals Ltd., India) Versus Felodipine Extended-Release Tablets USP 10 mg (R [NCT01630655]Phase 10 participants InterventionalCompleted
An Open Label, Randomised, 2-period, 2-treatment, 2-sequence, Cross-over, Single-dose Bioequivalence Study of Felodipine Extended-Release Tablets USP 10 mg (Test, Torrent Pharmaceuticals Ltd., India) Versus Felodipine Extended-Release Tablets USP 10 mg (R [NCT01630902]Phase 10 participants InterventionalCompleted
A Multi-center, Randomized, Open-label, Parallel-group Clinical Study to Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for the Treatment of Patients With Mild-to-Moderate Hypertension [NCT01520285]Phase 4281 participants (Actual)Interventional2011-12-31Completed
A Randomized, Open-label Study to Evaluate the Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release, Alone and in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide, in Chin [NCT02336607]529 participants (Actual)Interventional2005-12-31Completed
Action to Control Cardiovascular Risk in Diabetes (ACCORD) [NCT00000620]Phase 310,251 participants (Actual)Interventional1999-09-30Completed
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Felodipine Extended Release Tablet (Containing Felodipine 10 mg) of OHM Laboratories Inc (A Subsidiary of Ranbaxy Pharmace [NCT02327247]48 participants (Actual)Interventional2008-09-30Completed
The CORONAvirus Disease 2019 Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker InvestigatiON (CORONACION) Randomized Clinical Trial [NCT04330300]Phase 42,414 participants (Anticipated)Interventional2020-04-30Suspended(stopped due to Challenges with funding and very low incidence of COVID-19 at Irish study site)
Phase 1 Study of the Hemodynamic and Pharmacokinetic Interactions Between Coffee and Felodipine [NCT02232269]Phase 113 participants (Actual)Interventional2012-02-29Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00000620 (6) [back to overview]Death From Any Cause in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.
NCT00000620 (6) [back to overview]First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.
NCT00000620 (6) [back to overview]First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.
NCT00000620 (6) [back to overview]Stroke in the Blood Pressure Trial.
NCT00348686 (6) [back to overview]Change of Diastolic Blood Pressure (DBP)
NCT00348686 (6) [back to overview]Change of Systolic Blood Pressure (SBP)
NCT00348686 (6) [back to overview]LVH(Left Ventricular Hypertrophy) Regression by Echocardiac Parameter, Left Ventricular Mass Index
NCT00348686 (6) [back to overview]Percent Change of B Type Natriuretic Peptides (BNP) Level
NCT00348686 (6) [back to overview]Percent Change of proBNP(B Type Natriuretic Peptides) in Patients Treated With Candesartan Only
NCT00348686 (6) [back to overview]Percent Change of proBNP(B Type Natriuretic Peptides) in Patients With Candesartan Plus Felodipine
NCT02336607 (12) [back to overview]The Change of Pulse Wave Velocity at 12 Weeks Compare With Baseline Data of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 14 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]The Change of Pulse Wave Velocity From Baseline at 2, 14 Weeks of Felodipine Sustained Release Alone.
NCT02336607 (12) [back to overview]The Magnitude of Systolic and Diastolic Blood Pressure Change From Baseline Among All Randomized Subjects After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among All Randomized Subjects After 12 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among All Randomized Subjects After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 12 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.
NCT02336607 (12) [back to overview]The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 2 Weeks of Felodipine Sustained Release, Alone
NCT02336607 (12) [back to overview]The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.

Death From Any Cause in the Glycemia Trial.

"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control391
Glycemia Trial: Standard Control327

[back to top]

First Occurrence of a Major Cardiovascular Event (MCE); Specifically Nonfatal Heart Attack, Nonfatal Stroke, or Cardiovascular Death (Measured Throughout the Study) in the Glycemia Trial.

"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years

Interventionparticipants (Number)
Glycemia Trial: Intensive Control503
Glycemia Trial: Standard Control543

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Blood Pressure Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control208
BP Trial: Standard Control237

[back to top]

First Occurrence of Major Cardiovascular Event (MCE) in the Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate291
Lipid Trial: Placebo310

[back to top]

First Occurrence of MCE or Revascularization or Hospitalization for Congestive Heart Failure (CHF) in Lipid Trial.

Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
Lipid Trial: Fenofibrate641
Lipid Trial: Placebo667

[back to top]

Stroke in the Blood Pressure Trial.

Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years

Interventionparticipants (Number)
BP Trial: Intensive Control36
BP Trial: Standard Control62

[back to top]

Change of Diastolic Blood Pressure (DBP)

"Change of Diastolic Blood Pressure was calculated and collected through the way of Last Observational carried forward.~Only who has diastolic blood pressure data both baseline and follow up was analyzed. Most of patient who enrolled, 302 have a data." (NCT00348686)
Timeframe: At Baseline and 24 weeks

InterventionmmHg (Median)
Candesartan-20.0

[back to top]

Change of Systolic Blood Pressure (SBP)

Change of Systolic Blood Pressure was calculated and collected through the way of Last Observational carried forward. (NCT00348686)
Timeframe: At Baseline and 24 weeks

InterventionmmHg (Median)
Candesartan-32.0

[back to top]

LVH(Left Ventricular Hypertrophy) Regression by Echocardiac Parameter, Left Ventricular Mass Index

Change of Left Ventricular Hypertrophy(LVH) by Echocardiac Parameter, Left Ventricular mass Index (LVMI) was calculated and collected through the way of Last Observational carried forward. LVH/Index was calculated like this: Divide LV mass with Body Surface Area. (NCT00348686)
Timeframe: At Baseline and 24 weeks

Interventiong/m^2 (Median)
Candesartan-10.90

[back to top]

Percent Change of B Type Natriuretic Peptides (BNP) Level

Change of B Type Natriuretic Peptides Level of the Subjects With Hypertension and Left Ventricular Hypertrophy (LVH) Treated With Candesartan Based Therapy for 24 Weeks was calculated just as the later time point minus the earlier time point. No specific calculation was used. (NCT00348686)
Timeframe: At Baseline and 24 weeks

InterventionPercent Change (Median)
Candesartan-29.2

[back to top]

Percent Change of proBNP(B Type Natriuretic Peptides) in Patients Treated With Candesartan Only

Percent change of proBNP(B type Natriuretic Peptides) was calculated and collected through the way of Last Observational carried forward. (NCT00348686)
Timeframe: At Baseline and 24 weeks

Interventionpercent change (Median)
Candesartan-18.9

[back to top]

Percent Change of proBNP(B Type Natriuretic Peptides) in Patients With Candesartan Plus Felodipine

Percent change of proBNP(B type Natriuretic Peptides) was calculated and collected through the way of Last Observational carried forward. (NCT00348686)
Timeframe: At Baseline and 24 weeks

Interventionpercent change (Median)
Candesartan-36.1

[back to top]

The Change of Pulse Wave Velocity at 12 Weeks Compare With Baseline Data of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.

The duration of the combination therapy was 12 weeks. The change of pulse wave velocity was measured at week 14 of the trial. (NCT02336607)
Timeframe: 12 weeks

Interventionm/s (Mean)
Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK)-0.12
Felodipine Tablets (Plendil)+Lisinopril (Zestril)-0.44
Felodipine Tablet (Plendil)+Hydrochlorothiazide-0.06
Felodipine Tablet (Plendil)NA

[back to top]

The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 14 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.

(NCT02336607)
Timeframe: 14 weeks

InterventionPercentage (Number)
Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK)74.1
Felodipine Tablets (Plendil)+Lisinopril (Zestril)80.5
Felodipine Tablet (Plendil)+Hydrochlorothiazide80.2
Felodipine Tablet (Plendil)NA

[back to top]

The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.

The duration of the combination therapy was 4 weeks. Blood pressure was measured at week 6 of the trial. (NCT02336607)
Timeframe: 4 weeks

InterventionPercentage (Number)
Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK)45.8
Felodipine Tablets (Plendil)+Lisinopril (Zestril)59.5
Felodipine Tablet (Plendil)+Hydrochlorothiazide46.2
Felodipine Tablet (Plendil)NA

[back to top]

The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.

The duration of the combination therapy was 8 weeks. Blood pressure was measured at week 10 of the trial. (NCT02336607)
Timeframe: 8 weeks

InterventionPercentage (Number)
Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK)78.6
Felodipine Tablets (Plendil)+Lisinopril (Zestril)79
Felodipine Tablet (Plendil)+Hydrochlorothiazide78.7
Felodipine Tablet (Plendil)NA

[back to top]

The Change of Pulse Wave Velocity From Baseline at 2, 14 Weeks of Felodipine Sustained Release Alone.

The duration of the combination therapy was 12 weeks. The change of pulse wave velocity was measured at week 14 of the trial. (NCT02336607)
Timeframe: 12 weeks

,,,
Interventionm/s (Mean)
week 2week 14
Felodipine Tablet (Plendil)-0.58-0.86
Felodipine Tablet (Plendil)+HydrochlorothiazideNANA
Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK)NANA
Felodipine Tablets (Plendil)+Lisinopril (Zestril)NANA

[back to top]

The Magnitude of Systolic and Diastolic Blood Pressure Change From Baseline Among All Randomized Subjects After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.

The duration of the combination therapy was 4 weeks. Blood pressure was measured at week 6 of the trial. (NCT02336607)
Timeframe: 4 weeks

,,,
InterventionmmHg (Mean)
Change of systolic blood pressureChange of diastolic blood pressure
Felodipine Tablet (Plendil)NANA
Felodipine Tablet (Plendil)+Hydrochlorothiazide-9.8-6.0
Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK)-10.3-7.3
Felodipine Tablets (Plendil)+Lisinopril (Zestril)-13.4-9.9

[back to top]

The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among All Randomized Subjects After 12 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.

The duration of the combination therapy was 12 weeks. Blood pressure was measured at week 14 of the trial. (NCT02336607)
Timeframe: 12 weeks

,,,
InterventionmmHg (Mean)
Change of systolic blood pressureChange of diastolic blood pressure
Felodipine Tablet (Plendil)NANA
Felodipine Tablet (Plendil)+Hydrochlorothiazide-16.8-10.6
Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK)-16.6-10.7
Felodipine Tablets (Plendil)+Lisinopril (Zestril)-18.0-12.8

[back to top]

The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among All Randomized Subjects After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.

The duration of the combination therapy was 8 weeks. Blood pressure was measured at week 10 of the trial. (NCT02336607)
Timeframe: 8 weeks

,,,
InterventionmmHg (Mean)
Change of systolic blood pressureChange of diastolic blood pressure
Felodipine Tablet (Plendil)NANA
Felodipine Tablet (Plendil)+Hydrochlorothiazide-16.4-10.7
Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK)-17.8-11.3
Felodipine Tablets (Plendil)+Lisinopril (Zestril)-18.0-12.1

[back to top]

The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.

The duration of the combination therapy was 8 weeks. Blood pressure was measured at week 10 of the trial. (NCT02336607)
Timeframe: 8 weeks

,,,
InterventionmmHg (Mean)
Change of systolic blood pressureChange of diastolic blood pressure
Felodipine Tablet (Plendil)NANA
Felodipine Tablet (Plendil)+Hydrochlorothiazide-18.5-11.5
Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK)-19.4-13.4
Felodipine Tablets (Plendil)+Lisinopril (Zestril)-19.7-13.1

[back to top]

The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 12 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.

The duration of the combination therapy was 12 weeks. Blood pressure was measured at week 14 of the trial. (NCT02336607)
Timeframe: 12 weeks

,,,
InterventionmmHg (Mean)
Change of systolic blood pressureChange of diastolic blood pressure
Felodipine Tablet (Plendil)NANA
Felodipine Tablet (Plendil)+Hydrochlorothiazide-18.2-12.2
Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK)-18.4-13.0
Felodipine Tablets (Plendil)+Lisinopril (Zestril)-20.3-13.6

[back to top]

The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 2 Weeks of Felodipine Sustained Release, Alone

The duration of the combination therapy was 2 weeks. Blood pressure was measured at week 2 of the trial. (NCT02336607)
Timeframe: 2 weeks

,,,
InterventionmmHg (Mean)
Change of systolic blood pressureChange of diastolic blood pressure
Felodipine Tablet (Plendil)-22.8-15.1
Felodipine Tablet (Plendil)+HydrochlorothiazideNANA
Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK)NANA
Felodipine Tablets (Plendil)+Lisinopril (Zestril)NANA

[back to top]

The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide.

The duration of the combination therapy was 4 weeks. Blood pressure was measured at week 6 of the trial. (NCT02336607)
Timeframe: 4 weeks

,,,
InterventionmmHg (Mean)
Change of systolic blood pressureChange of diastolic blood pressure
Felodipine Tablet (Plendil)NANA
Felodipine Tablet (Plendil)+Hydrochlorothiazide-16.4-8.2
Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK)-16.1-12.3
Felodipine Tablets (Plendil)+Lisinopril (Zestril)-17.1-10.9

[back to top]